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13-Cis-retinoic acid (13-cis-RA) is a synthetic retinoid and the active ingredient 
in the oral acne treatment Accutane.  The medical literature has suggested that the use of 
13-cis-RA for acne treatment can induce depression, but because acne itself can have a 
negative psychosocial impact on self esteem, whether or not 13-cis-RA can cause 
depression remains controversial.  The purpose of this work was to examine whether 
chronic 13-cis-RA administration could induce depression-related behaviors in mice and 
to determine the impact 13-cis-RA has on regions of the brain thought to be associated 
with mood and depression.  We found that chronic treatment of adolescent male mice 
with 13-cis-RA induced depression-related behaviors, as assessed by immobility in the 
tail suspension and forced swim tests.  Although depression is a multifaceted disease in 
which many brain regions are involved, the regions that seem particularly vulnerable to 
the effects of 13-cis-RA are the serotonergic and hippocampal systems.  In serotonergic 
cells in vitro, 13-cis-RA treatment increases protein levels of the serotonergic 5-HT1A 
autoreceptor and the serotonin reuptake transporter (SERT), two inhibitory components 
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of serotonin (5-HT) signaling.  In vivo, the median and dorsal raphe nuclei contain the 
main 5-HT producing cells.  13-Cis-RA uncoupled the functional connectivity of dorsal 
raphe nuclei from the hippocampal regions as measured by interregional correlations of 
cytochrome oxidase (CO) activity, a metabolic marker of neuronal activity.  Decreased 
hippocampal neurogenesis is thought to occur in depression and is decreased by 13-cis-
RA. 5-HT is also a known regulator of hippocampal neurogenesis.  Uncoupling of the 
dorsal raphe nuclei from the regions of the hippocampus by 13-cis-RA treatment may be 
the cause of, or a result from, the decreased neurogenesis.   Although retinoids are known 
regulators of apoptosis, the uncoupling of the dorsal raphe nuclei from the hippocampal 
regions was not due to serotonergic cell loss.  Interestingly, 13-cis-RA treated animals 
with the lowest CO activity in the dentate gyrus have the highest immobility in the tail 
suspension and forced swim tests.  Ultimately, the effects of 13-cis-RA on the 
serotonergic and hippocampal systems might be inducing depression-related behaviors.  
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Chapter 1: Introduction and Literature Review 
GENERAL OVERVIEW OF RETINOIDS 
Chemical Classification and Structure 
Retinoids are a class of compounds derived from vitamin A (retinol) that are 
found in the diet as retinyl esters or β-carotene.  Retinyl esters are consumed in foods 
such as whole milk, liver, egg yolks, oily fish, butter and cheese. β-carotene is found in 
many fruits and vegetables, including red peppers, carrots, broccoli, spinach, some herbs, 
apricots and mangos.  Retinyl esters and β-carotene are converted to retinol (Fig. 1.1A 
and 1.1B) in the intestinal lumen and mucosa, respectfully, where retinol is then 
absorbed.  Once absorbed by the gut, retinol is converted back to retinyl esters and 
packaged with other lipids in chylomicrons that are transported to the liver (1).   
Retinol binds to retinol binding protein (RBP) and is secreted into the blood to be 
transported to cells through circulation.  Due to its lipophylic properties, retinol can 
diffuse freely across cell membranes to bind cellular retinol binding protein (CRBP), 
which can transport retinol throughout the cytosol (Fig. 1.2).  Once in a cell, retinol can 
be converted back to retinyl esters for storage by lecithin retinol acetyltransferase 
(LRAT) or metabolized to its active form, all-trans-retinoic acid (ATRA).  Metabolism 
of ATRA is a two step, enzymatically driven process: 1) the reversible reaction of a 
conversion of retinol to retinaldehyde by retinol dehydrogenase (ROLDH) or alcohol 
dehydrogenase (ADH) and 2) conversion of retinaldehyde to ATRA by 
retinaldehydrogenase (RALDH) (1).  ATRA can be degraded to its inactive form, 4-oxo-
retinoic acid, by the phase I cytochrome P450 enzyme CYP26A1 (2). 
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Serum levels of retinol are 0.5 to 2 µM and the physiological level of ATRA is 14 
nM, although pharmacological levels of ATRA could be around 10 µM.  Increases in 
dietary vitamin A do not lead to an increase in serum levels of retinol bound to 
chylomicrons or free retinol, but does lead to an increase in tissues that have the capacity 
to store retinol as retinyl esters, such as the liver. 
ATRA is transported through the blood bound to albumin (3) and 
pharmacokinetic studies of synthetic analogs of ATRA, such as 13-cis-retinoic acid (13-
cis-RA), indicate that they are absorbed in the same way as ATRA [reviewed in (4)].  It 
has been shown in rats that most tissues derive 5-30% of the ATRA within that tissue 
from circulating ATRA (5).  However, the brain and the liver derive greater than 80% of 
their ATRA from the circulating pool (5).  
 
13-Cis-Retinoic Acid 
13-Cis-RA (isotretinoin) is the active ingredient in the acne medication, Accutane.  
It is administered to humans as a soft-gelatin oral capsule (6).  13-Cis-RA is a synthetic 
retinoid and isomer of ATRA.  The drug Accutane was approved for use in 1982 to treat 
severe nodular acne and it was originally intended to treat cases where acne was resistant 
to antibiotic or topical retinoid treatment (7).  
According to the Roche Accutane insert, side effects of Accutane use include 
headaches, blurred vision or loss of night vision, dizziness, nausea or vomiting, seizures, 
diarrhea or rectal bleeding, and decreased bone density (6).  Additionally, the insert 
reports that “Accutane use may cause depression, psychosis, and, rarely, suicidal 
ideation, suicide attempts, suicide, and aggressive and/or violent behaviors” (6). 
In patients aged 12-15 chronically taking 13-cis-RA, the maximum plasma 
concentration of 13-cis-RA ranged from 370 ng/mL (1.2 µM) to 1,094 ng/mL (3.6 µM) 
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with the median concentration being 750 ng/mL (2.5 µM) (6).  Adult plasma 
concentrations were not found to be significantly different (6).  The time required to 
reach this peak plasma concentration ranges from 4 to 8 hours (6, 8), while the half-life of 
elimination is approximately 21 hours (6).  The metabolites of 13-cis-RA found in 
patients are 13-cis-4-oxo-retinoic acid, ATRA, and 4-oxo-retinoic acid (6, 8). 
 
Mechanism of Action 
The retinoids have varying affects on several biological phenomena including 
cellular differentiation, embryonic central nervous system and limb development, vision, 
reproduction, and the immune response.  ATRA is the most active naturally occurring 
retinoid.  ATRA binds to cellular retinoic acid binding proteins I and II (CRABP I and II) 
for transport throughout the cytosol (Fig. 1.2).  It is thought that CRABP I promotes 
catabolism of ATRA by transporting it to CYP261A while CRABP II has been suggested 
to shuttle ATRA to the nucleus where ATRA is capable of initiating transcription.  Once 
in the nucleus, ATRA binds to the retinoic acid receptors (RAR-α, -β, and -γ) that 
heterodimerize with retinoid X receptors (RXR-α. –β, and -γ).  The RAR/RXR 
heterodimers bind to recognition sequences in the promoter region of genes known as 
retinoic acid response elements (RARE).  Once ligand bound by ATRA, transcription is 
activated.   
The exact mechanism by which 13-cis-RA reduces sebum production and 
stabilizes keratinization are unknown, but 13-cis-RA is thought to affect transcription in 
cells by one of two ways.  First, 13-cis-RA can isomerize to ATRA (Fig. 1.3) and then 
bind to the RAR to initiate transcription (9).  Second, 13-cis-RA can itself bind to the 
RAR to initiate transcription (10).  The affinity of 13-cis-RA for the RAR is much lower 
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than ATRA, but the activation of the RAR, and therefore subsequent transcription, is very 
effective (10).   
13-Cis-RA reduces sebaceous gland size (11) and sebum production (12) in 
humans and is capable of inducing apoptosis and cell cycle arrest in immortalized 
sebaceous glands in a non-RAR dependent fashion (13).  Additionally, the effects of 13-
cis-RA on immortalized sebaceous glands are either not seen due to ATRA treatment, or 
happen much longer after treatment with ATRA (13).  Retinoids are also capable of 
affecting cells via non-transcription mediated methods, such as mRNA stability and 
protein stability. Although the mechanism is not completely understood, ATRA can 
reduce TNF-α mRNA stability in a RXR-mediated manner in hepatocytes (14), increase 
keratin 19 mRNA stability in cultured keratinocytes (15) and increase protein stability in 
P19 cells (16).  Thus, although 13-cis-RA is capable of isomerizing to ATRA to act 
through the RAR, or acting through the RAR itself, the effects of Accutane treatment 
may be due to 13-cis-RA acting in a non-RAR-mediated manner.  
 
RETINOID SIGNALING MACHINERY IN THE ADULT CENTRAL NERVOUS SYSTEM 
ATRA has been found in the adult brain, with the highest levels being found in 
the hippocampus (17).  Although retinoids are lipid soluble and thus capable of easily 
crossing the blood brain barrier, the adult cerebrum, cerebellum, meninges and pia matter 
have the capability of synthesizing ATRA (18-20).  CRBP and CRABP are also 
expressed in the adult brain (21).  Cellular retinoic acid binding protein I is thought to 
shuttle ATRA to the nucleus where it can then activate gene transcription and is found 
throughout the adult brain including the cortex, amygdala, hippocampus, thalamus, and 
substantia nigra with high expression occurring in the hypothalamus (21).   
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The presence of CRABPI may indicate that ATRA is shuttled to the nucleus so 
that it can activate gene transcription in the adult brain.  RAR expression is distributed 
throughout hippocampus, cortex (RARα), caudate/putamen, nucleus acumbens and 
olfactory tubercle (RARβ and γ) (21) and differs between developing and adult brains, 
implying a physiological role for retinoids in the adult brain (22).  The presence of RARs 
indicates gene transcription by ATRA occurs in the adult brain, regulating gene 
expression in areas such as the hippocampus and cortex.  Additionally, high levels of 
CYP26A1, which degrades ATRA, are expressed in the adult cerebellum (23).  The 
ability to regulate ATRA levels indicates the adult brain is susceptible to high levels of 
retinoids.  The dopamine receptor 2 (D2R) has been found to contain a functional RARE 
(24).  Other genes known to regulated by ATRA are tyrosine hydroxylase (an enzyme 
involved in dopamine production) and dopamine β-hydroxylase (25, 26).  The presence 
of enzymes to produce ATRA, the proteins to shuttle ATRA to the nucleus and the 
proteins to bind ATRA and induce gene transcription along with the presence of RAREs 
in regulating regions of genes expressed in the adult central nervous system indicates a 
role for retinoids in regulating gene transcription and cell signaling in the adult brain.   
The ability of retinoids to exert effects in the adult CNS is further implied in the medical 
literature by the ability of 13-cis-RA to induce depression in humans.  
 
EFFECTS OF RETINOIDS ON THE DOPAMINERGIC AND NOREPINEPHRINERGIC 
SYSTEMS 
Norepinepherine (NE) has been implicated in depression based on much clinical 
data, for example depressed patients exhibit lower urinary levels of the NE metabolite, 3-
methoxy-4-hydroxy-phenylglycol (27).  In the transthyretin null mouse retinol transport 
would theoretically be reduced, and thus the cellular levels of ATRA would also be 
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decreased.  Interestingly, tissue NE levels were increased in limbic forebrain of the 
transthyretin null mouse (28) suggesting that retinoids may influence norepinephrinergic 
transmission.  However, the effect of retinoids on brain NE levels has not been directly 
examined. 
The mesolimbic DA system is a key element of the brain’s motivational and 
reward system and its dysregulation in depression may underlie symptoms of anhedonia 
[for reviews see (29, 30)].  Repeated treatment with antidepressants increases dopamine 2 
(D2) receptor binding (31).  ATRA has been shown to increase D2 receptor expression in 
the striatum (24, 32) and in cultured cells via activation of a functional RARE in its 
promoter region (33).  RARβ/RXRβ, RARβ/RXRγ, and RXRβ/RXRγ double null mice 
have decreased expression of D2 receptor (34).  This is not true for the corresponding 
single null mice.  Additionally, transcription of tyrosine hydroxylase and dopamine β 
hydroxylase, the enzymes involved in DA synthesis, is decreased by ATRA in rat 
superior cervical ganglia neurons (26, 35, 36).  However, the tyrosine hydroxylase 
promoter is activated by ATRA in human neuroblastoma cells (37).   Monoamine oxidase 
B activity, which is primarily responsible for the degradation of DA to 
dihydroxyphenylacetic acid (DOPAC), is increased by ATRA in chick hepatocytes (38). 
In addition, the level of homovanillic acid, the final degradative product of DA, appeared 
to be elevated in the striatal tissue of male rats treated with 13-cis-RA (39).  Consistent 
with this, DOPAC was decreased in the striatal tissue of vitamin A deficient mice and 




General Overview of Depression 
Mood disorders, including major depressive disorder, affect approximately 10% 
of the population (41).  Depression is a very serious, debilitating disease.  Symptoms of 
depression include extreme sadness, feelings of helplessness, lack of interest in pleasure 
seeking (termed anhedonia), decreased sleep or oversleeping, loss of energy, weight loss 
or weight gain, irritability, and difficulty focusing and remembering.  Additionally, 
depressed patients may experience headaches or chronic pain that are not responsive to 
treatment.  Ultimately depressed patients may have thoughts of suicide or exhibit suicidal 
behavior.   
Antidepressant treatment for depression usually targets the serotonergic, 
norepinepherinergic, or dopaminergic systems or some combination thereof.  These 
antidepressants work to increase the levels of the respective monoamine within hours 
after administration of the drugs (42).  However, antidepressant mood-elevating effects 
are often not observed until about two weeks after antidepressant treatment is initiated 
(42), indicating that other processes outside of monoamine neurotransmission are 
involved in mood regulation.  Brain regions thought to be involved in depression and 
relevant to this dissertation include the orbitofrontal cortex, the hippocampus, the 
habenula, and the raphe nuclei.  
  
Behavioral Tests  
Because some of the information about the brain regions involved in depression 
was gained through behavioral studies in animals, it is important to first discuss the 
behavioral paradigms.  The tail suspension and forced swim tests are two behavioral 
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despair paradigms in which an animal is placed in an inescapable, stressful situation and 
the amount of time spent trying to escape the situation is assessed.  In both tests, 
administration of antidepressants to an animal will increase the amount of time the 
animal spends struggling (43, 44).  In the tail suspension test, the animal is suspended by 
the tail and escape behaviors involve thrashing of the body and both fore- and hindpaw 
movement.  Immobility consists of either hanging straight, but motionless, or curled up 
with the forepaws holding onto the hindlegs.  There is very little movement of the paws 
in immobility, although grooming may occur.  
In the forced swim test, the animal is placed in a cylindrical bath of room 
temperature water in which the animal cannot touch the bottom of the container to stand, 
nor can it reach the top of the container to get out.  Behaviors in this paradigm are 
assessed as swimming, climbing, or immobility.  Swimming is considered circular 
movement around the cylinder, while climbing behavior involves the animal becoming 
vertical and pawing at the walls of the cylinder.  Immobility is considered to be 
movement necessary for the animal to keep its head above water (44). 
Because the immobility in these two tests is reduced by antidepressants and 
antidepressants are mood elevators in humans, the amount of time spent immobile is 
considered a depression-related behavior.  One limitation of this test is that antidepressant 
treatment to rodents can decrease immobility in these two behavioral tests immediately 
after administration, while antidepressant efficacy can take weeks in humans.  Therefore, 
it may seem more reasonable to use immobility in the tail suspension and forced swim 
tests to assess potential antidepressant efficacy of drugs.  However, factors known to 
cause depression in humans can increase the amount of time spent immobile.  For 
example, increased immobility in the forced swim test has been reported to occur in 
situations that increase vulnerability to depression such as estradiol deficiency due to 
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aromatase knockout (45), stress due to food restriction (46), magnesium depletion (47), 
and choline administration (48).  The behavior of the animals in the tail suspension test 
was not assessed in these studies.  Increased immobility in both the forced swim and tail 
suspension tests does occur due to the pro-depressant effects of withdrawal from chronic 
amphetamine administration (49), centrally administered urotensin-II (50), and 
interleukin-1 and endotoxin injection (51).  Thus, immobility appears to be a good 
measure of depression-related behavior. 
 
Brain Systems Involved in Depression 
Raphe Nuclei 
The median and dorsal raphe nuclei are the main serotonin (5-hydroxytryptamine 
or 5-HT) producing cells in the brain thought to be involved in mood and cognition (52, 
53).  The serotonergic system is very commonly a target of antidepressant treatments and 
such treatments work to increase serotonergic signaling.  Lesions to the lateral habenula, 
a major regulator of the monoaminergic systems, increase 5-HT in the dorsal raphe 
nuclei, and can also decrease depression-related behaviors.  Tryptophan is the precursor 
for 5-HT synthesis and tryptophan depletion studies result in depleted 5-HT levels after 
approximately 5 hours.  Tryptophan depletion induces depression in healthy subjects with 
a family history of depression (54-56) and in non-medicated, remitted patients with a 
history of depression (57-59).  However, tryptophan depletion does not induce depressive 
symptoms in healthy patients with no family history of depression (60), suggesting that 
depression is a multifaceted disease requiring more than just dysfunctional serotonergic 
signaling.  Further confounding the role of 5-HT in depression, rats with denervation of 
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the dorsal and median raphe nuclei do not exhibit increased depression-related behaviors 
in the forced swim test (61, 62).   
 
Hippocampus 
Neurogenesis in the hippocampus is also thought to be involved in depression and 
hippocampal volume has been found to be decreased in depressed patients (63-66).  
Furthermore, antidepressant drugs have been found to increase hippocampal neurogenesis 
after several weeks of administration (67), which is concordant with the elevation of 
mood due to antidepressant treatment.  However, it is not known if reduced hippocampal 
neurogenesis causes or results from depression in humans.   
Many factors coordinate adult hippocampal neurogenesis including 5-HT, stress, 
steroids and neurotrophic factors [for reviews see (68, 69)].  5-HT itself has been 
implicated in the mechanisms of adult neurogenesis largely on the basis of the actions of 
antidepressants that elevate 5-HT levels (e.g. fluoxetine) and have been shown to 
promote neurogenesis (67).  In addition, SSRIs and monoamine oxidase inhibitors can 
also increase brain-derived neurotrophic factor in the hippocampus which could provide 
an alternative mechanism whereby 5-HT could regulate adult neurogenesis [for reviews 
see (68, 69)]. 
 
Habenula 
As a major regulator of the monoaminergic systems, it is not surprising that the 
habenula might have a role in depression-related behaviors.  Although little is known 
about the possible role of the habenula in depression, the habenula receives afferent 
projections from the serotonergic and noradrenergic systems (70, 71) as well as sending 
 11 
efferent projections to the dopaminergic ventral tegmental area (71).  In addition, the 
lateral habenula negatively regulates the dorsal raphe nuclei (72) and lesions of the lateral 
habenula in stress-induced depressed rats leads to an increase in 5-HT in the dorsal raphe 
nuclei as well as decreased immobility, due to increased climbing behavior, in the forced 
swim test (73).  The lateral habenula has been found to be significantly hypermetabolic in 
congenitally learned-helpless rats as compared to congenitally non-helpless rats, a rat line 
that is resistant to learned helpless behavior (74). 
 
Orbitofrontal Cortex 
Metabolic mapping studies have shown that various areas of the frontal cortex 
may be altered in depression.  In depressed patients that are responsive to antidepressant 
treatment, orbitofrontal cortex metabolism is higher than in healthy individuals (75).  
However, the orbitofrontal cortex metabolism is either not changed or is decreased in 
depressed patients that are resistant to antidepressant treatment (75).  Additionally, 
neuronal and glial cell densities are also reduced in the orbitofrontal cortex of depressed 
suicide victims (76, 77).   
 
ACCUTANE AND DEPRESSION 
Human Studies 
Since approval of Accutane in 1982 to treat severe cystic acne, numerous reports 
concerning the ability of Accutane to induce depression and suicidal ideation have 
appeared throughout the medical literature indicating an incidence of depressive 
symptoms in approximately 8% of patients (78).  Between 1982 and 2002 the US FDA 
Adverse Event Reporting System received approximately 394 reports of depression and 
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37 suicides related to the use of Accutane (79).  In some cases, depressive symptoms 
were reported to resolve once Accutane use was discontinued [for review see (80)].  
Additionally, some cases report recurrence of symptoms upon rechallenge with 13-cis-
RA (81).  Since the mid-1980s, reports in the literature suggest a relationship between 13-
cis-RA use and the onset of psychological symptoms including depression, suicidal 
ideation and psychosis (79, 82-88).  However, there are also studies suggesting that there 
is no evidence of such a link (89-92) and the epidemiological evidence has remained 
contradictory [e.g. (90) versus (87)].  For instance, Jick et al. (89) conducted an 
epidemiological study in which no link was found between Accutane and major 
depressive disorder, although other types of depression were not examined.   Another 
epidemiological study conducted by Hersom et al. (93) examined a pharmacy database to 
determine if patients that had filled isotretinoin prescriptions had a higher rate of 
sequentially filling antidepressant prescriptions.  These authors reported that patients 
filling isotretinoin prescriptions do not have a higher incidence of then filling an 
antidepressant prescription, and thus concluded that there is not an association between 
isotretinoin use and depression (93).  However, the authors did not take into 
consideration that patients that take isotretinoin and experience depressive symptoms 
may simply stop taking the medication rather than seeking prescriptions for 
antidepressants.  Additionally, the two above-mentioned studies that did not find a link 
between isotretinoin and depression were both funded by Roche, the manufacturer of 
Accutane. 
Bremner et al. (94) evaluated humans administered 13-cis-RA for acne treatment 
and compared them to antibiotic controls.  PET scans taken before and after four months 
of treatment revealed a decrease in orbitofrontal cortex glucose metabolism following 13-
cis-RA treatment (94).  Patients who received antibiotic treatment had no change in 
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orbitofrontal cortex glucose metabolism before or after treatment (94).  Although some 
patients taking 13-cis-RA reported headaches and subtle changes in irritability or mood, 
none of them were found to be clinically depressed, as assessed by the Hamilton 
Depression Scale (94).  This study was done as a small pilot study and therefore the 
treatment groups were not randomly assigned and the sample size was small.  
Additionally, patients who had a history of mental illness were excluded from the study.  
These factors could conceal mood-related changes that may be seen following 13-cis-RA 
treatment in a larger population. 
 
Animal Studies 
Decreased neurogenesis has been associated with mood disorders, including 
depression [for reviews see (63, 64)].  The phenomenon of adult neurogenesis, where 
new neurons proliferate and become functionally integrated with existing neurons, has 
been most widely studied in the hippocampus (95, 96).  Long-term retinoid treatment in 
vivo decreases adult hippocampal neurogenesis (97).  Specifically, when young adult 
CD1 mice were treated with 13-cis-RA (1mg/kg/day) for up to 6 weeks, a significant 
decrease in hippocampal neurogenesis was observed (97).  Although these authors did 
not examine depression-related behaviors, they did demonstrate that 13-cis-RA treatment 
leads to impaired spatial learning and memory performance in the radial arm maze. 
Only one other group has conducted studies examining the effects of 13-cis-RA 
on depression-related behavior in animals.  Ferguson et al. (98) treated adult rats with 7.5 
or 22.5 mg/kg/day 13-cis-RA or 10 or 15 mg/kg/day of ATRA and found no differences 
in depression-related behavior in the forced swim test.  Ferguson et al. (98) examined 
adult rats with treatment starting at 12 weeks and continuing to approximately 19 weeks 
of age and 13-cis-RA was administered via oral gavage.  Although the authors did not 
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report serum levels, they state that the 7 or 15 mg/kg/day dose of 13-cis-RA or ATRA 
was required to elevate the rat serum level to that measured in humans taking Accutane 
(98).  These doses of 13-cis-RA are much higher than the prescribed doses for human 
patients, which vary between 0.5 and 2 mg/kg/day (6).   Additionally, Ferguson et al. (98) 
used oral gavage to administer the 13-cis-RA to the rats and this method of 
administration requires that the animal be restrained for a longer period of time than other 
methods of administration, such as intraperitoneal (i.p.) injection.  The animals were 
subjected to a two-day forced swim test, which is typically used to assess learned-
helplessness.  The second day is utilized as a measure of the animal’s learned response to 
become helpless.  Ferguson et al. (98) reported that the animals spent more time 
swimming on the second day of treatment.  In the learned-helpless paradigm, animals 
usually spend more time immobile on the second day.  The fact that Ferguson et al. (98) 
reported that control rats spend less time immobile on the second day indicates that this 
test was not performed correctly.  However, these authors report the swimming, climbing, 
and immobility measurements as an average from the two tests, making it difficult for the 
reader to assess their results. 
In a follow-up study by the same group, Ferguson et al. (99) again reported no 
change in depression-related behaviors due to 13-cis-RA treatment.  Treatment doses and 
method of administration were the same as in the first study.  In this second study, 
animals were tested in the two-day forced swim test three separate sessions at 24, 82, and 
130 days after treatment with vehicle or 13-cis-RA (99).  This group reported no effect of 
treatment on behavior for any of the test sessions.  Measurements of climbing, 
swimming, and immobility were reported as an average of the three test sessions for 
either day one or day two (99).   Due to inappropriate presentation of the forced swim 
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test, these studies do not offer insight as to whether or not 13-cis-RA can induce 
depression.   
 
OVERVIEW 
The work that comprises this dissertation was directed at four aims.  The first aim 
was to determine if 13-cis-RA is capable of inducing depression-related behaviors in 
adolescent mice.  This aim is important because the epidemiological data indicating that 
13-cis-RA could cause depression is controversial.  Additionally, whether or not patients 
taking Accutane might become depressed due to 13-cis-RA is confounded by the 
psychosocial impact of acne on human self-image and self-esteem.  The use of an animal 
model allowed us to establish the effect of 13-cis-RA on behavior without the 
confounding social factor of acne and self-image.  The second aim was to determine the 
effects of 13-cis-RA on the serotonergic system.  The serotonergic system is commonly 
disrupted in depressed individuals and many antidepressants work through manipulating 
the serotonergic system.  The third aim was to determine the effects of 13-cis-RA 
administration on brain metabolism in adolescent mice using cytochrome oxidase (CO) 
as a metabolic measure because brain metabolism in depressed patients is altered in 
various brain regions.  The last aim is directed at determining the effects of 13-cis-RA on 
serotonergic cell numbers.  Retinoids are known to play a role in differentiation, cell 
cycle, and apoptosis.   Additionally, one theory of depression is that apoptosis is 
increased in depressed patients, thus the effects of 13-cis-RA on serotonergic cell 
numbers was examined.   
Chapter 2 discusses the effects of 13-cis-RA administration on depression- and 
anxiety-related behaviors in adolescent male mice.  Chapter 3 investigates the effects that 
13-cis-RA has on components of the serotonergic system in vitro.  Chapter 4 examines 
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the changes in brain metabolism due to 13-cis-RA administration.  Chapter 5 discusses 
the effects of 13-cis-RA on the cell death in serotonergic cells in vivo.  To conclude this 
study, Chapter 6 summarizes these studies and discusses future work that could be done 
in this field. 
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Figure 1.1: Cleavage of dietary vitamin A.   
(A) Retinyl Esters are cleaved in the lumen of the intestine and (B) β-carotene is cleaved 
in the intestinal mucosa to form Retinol adapted from (100). 
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Figure 1.2: Retinoid storage and mechanism of action. 
Retinol is transported through the blood bound to retinol binding protein (RBP).  Retinol 
crosses the cell membrane and is either converted to retinyl esters for storage or to all-
trans-retinoic acid (ATRA) via a retinol dehydrogenase (ROLDH) and retinaldehyde 
dehydrogenase (RALDH).  ATRA is then either further degraded to 4-oxo-retinoic acid 
(4-oxo-RA) and excreted or shuttled to the nucleus where it binds to the retinoic acid 
receptor (RAR).  In the nucleus, the RAR heterodimerizes with the retinoid X receptor 
(RXR) and binds to the retinoic acid response element in the DNA.  Once ATRA binds to 
the RXR/RAR heterodimer, transcription is initiated. 
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Figure 1.3: 13-Cis-RA mechanism of action. 
(A) 13-cis-RA is capable of isomerizing to ATRA.  (B) Once inside the cell, 13-cis-RA 
can isomerize to ATRA and then bind to the RAR in the nucleus to initiate transcription.  
Alternatively, 13-cis-RA can bind to the RAR in the nucleus and initiate transcription. 
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Chapter 2:  Chronic Administration of 13-Cis-RA Increases Depression-
Related Behavior in Mice 
ABSTRACT 
The use of 13-cis-RA to treat severe acne has been associated with onset of 
depression in the humans, although whether or not 13-cis-RA can cause depression has 
remained controversial.  Because the psychosocial impact of acne may play a factor in 
adolescent depression, an animal model was used to test the hypothesis that chronic 
administration of 13-cis-RA would lead to depression-related behaviors.  Young, adult 
male mice received 13-cis-RA (1 mg/kg) by daily i.p. injection for 6 weeks.  This 
treatment paradigm produced plasma levels of 13-cis-RA that are comparable to those 
reported in human patients taking Accutane.  In both the forced swim test and the tail 
suspension test we found that 13-cis-RA treated mice spent significantly more time 
immobile compared to vehicle treated controls.  In the open field test there was no change 
in anxiety-related behavior in 13-cis-RA treated mice.  Furthermore, chronic 
administration of 13-cis-RA did not impair locomotion in either the open field or the 
rotarod test.  Taken together these results suggest that administration of 13-cis-RA 
increases depression-related behaviors in mice. 
 21 
INTRODUCTION 
Accutane (13-cis-RA) was originally intended to treat severe acne that is resistant 
to other forms of treatment (7).  As mentioned previously, the medical literature indicates 
there may be a link between 13-cis-RA use and depression, although this link remains 
controversial.  Patients with disfiguring acne exhibit problems with self-esteem, self-
image, depression and anger (101).  These emotional responses to severe acne could, at 
least in part, be responsible for the depressive symptoms associated with 13-cis-RA use, 
thus confounding depressive symptoms arising due to 13-cis-RA treatment.  In an attempt 
to remove the psychosocial variables that could also cause depressive symptoms from our 
studies, a mouse model was used.  The use of an animal model allows for the separation 
of the effects of acne on self-image and mood from those of 13-cis-RA itself on 
depression-related behavior. 
Acne is most prevalent in adolescent populations (102), thus, Accutane is 
commonly prescribed to adolescents.  Adolescence in humans is considered the time of 
development during which the transition from childhood to adulthood occurs.  
Hallmarked not only by the greatest amount of growth and the development of sexual 
characteristics, adolescence is also comprised of the events that lead the individual from 
dependence on a primary caretaker to the ability to care for themselves [Reviewed in 
(103)].  Thus, adolescence in humans usually starts around 12 years of age and can end as 
late as 25 years old [Reviewed in (103)].   Our animal studies utilized the inbred DBA/2J 
mice strain (Jackson Laboratory, Harbor, MA).  Mice were three weeks upon arrival.  
Mice reach sexual maturity between the ages of six and eight weeks and the growth of the 
animals does not begin to slow until approximately 9 or 10 weeks of age (104), therefore 
mice aged 4 to 12 can be considered adolescent. 
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Retinoids, including vitamin A and its derivatives, have long been studied for 
their role in embryonic development because excess retinoids induce neural tube defects.  
Emerging evidence now indicates that retinoid signaling pathways also affect the 
functioning of the adult brain [For review see (105, 106)].  Inuit populations often 
consume high levels of vitamin A in the livers of seals, sharks and predatory mammals 
resulting in the phenomenon termed “pibloktoq”, also known as “artic hysteria” (107). 
Retinoid toxicity, similar to some of the side effects of 13-cis-RA treatment, manifests as 
intense headaches, due to increased intracranial pressure resulting from excess 
cerebrospinal fluid termed “pseudotumor cerebrei”, dry skin and hair loss, bone, joint, 
and muscle pain, fatigue and anorexia. In addition, hypervitaminosis A has been reported 
to induce psychosis (108, 109). Specifically, patients experiencing hypervitaminosis A 
exhibited depression, elevated anxiety, and irritability (107, 110).  It is unknown if the 
toxic effects of excess dietary vitamin A are mediated via ATRA or by retinol.  Although 
circulating retinol concentrations are maintained at 1-2 µM, ingestion of ATRA and 13-
cis-RA can raise serum levels of these retinoids well above physiological levels.  Due to 
their lipophillic nature, retinoids can cross the blood-brain barrier and affect various 
cellular processes both inclusive and exclusive of ATRA and RAR-mediated gene 
transcription (111-113).   
Given the role of retinoids in neuronal differentiation, it is not surprising that a 
large number of neuronal genes have been shown to be retinoid-responsive [For review 
see (106)].  Neuronal genes containing identified functional RARE in their promoter 
regions include the dopamine D2 receptor (24, 32, 114), neurogranin (RC3) (115, 116), 
gonadotrophin-releasing hormone (117, 118) and oxytocin (119).  Consequently, 
retinoid-responsive gene transcription in the central nervous system could have a 
significant impact on the function of the adult brain.  Indeed, such a role for retinoids has 
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been demonstrated in learning and memory (97, 120, 121).  In agreement with a role for 
retinoids in learning and memory, Crandall et al. (2004) have shown that long-term 
administration of 13-cis-RA in adult mice suppresses hippocampal neurogenesis (97).  
Deficits in adult neurogenesis in the hippocampus have been proposed to underlie 
depression (122), especially as they are sensitive to reversal by antidepressant 
administration (123).  Crandall et al. (2004) reported impairments in spatial learning but 
did not report an effect on depression-related behaviors in mice.   
The objective of the present study was to determine whether 13-cis-RA, 
administered in a dose identical to that prescribed to human patients, could alter 
depression- or anxiety-related behaviors in young adult mice.  Here, we report that 
chronic administration of 13-cis-RA increases the time spent immobile in both the forced 
swim and the tail suspension tests.  Increases in immobility in the behavioral despair 




Young, adult male DBA/2J (Jackson Laboratories, Bar Harbor, ME) mice were 
used in this study.  Male mice were chosen to avoid the effects of estrous cycle.  Animals 
were three weeks old at arrival and four weeks old at the start of treatment.  Mice were 
group housed four per cage and maintained under a 12:12 h light/dark cycle.  Food and 
water were provided ad libitum.  All procedures and tests performed on animals were 
approved by the University of Texas IACUC, protocol number 04100403, and according 




Animals were allowed to adapt to the University of Texas animal facility for one 
week prior to initial injection.  Animals were handled during the first week to reduce the 
stress of receiving daily injections.  A 2 mg/mL stock solution of 13-cis-RA in DMSO 
was stored for up to one week at -20 ºC.  The stability of 13-cis-RA after one week of 
storage was confirmed by comparing the absorbance at 354 nm to that of a freshly 
prepared sample (97).  Sterile injection samples were prepared in the dark.  Injections 
were performed one hour prior to the start of the dark cycle, to avoid waking the animals 
in the middle of their sleep cycle, and the injections were kept covered to prevent 
exposure to light until right before the injection was performed.  Injections were given in 
the same room where the animals were housed and the same person performed all 
injections.  Treated animals (n = 12) received daily intraperitoneal (i.p.) injections of 1 
mg/kg/day 13-cis-RA (Sigma, St. Louis, MO) dissolved in sterile 50% DMSO/50% 
saline (0.9%) to a final volume of 200 µL.  Control animals (n = 12) were administered 
200 µL of vehicle (50% DMSO/50% saline), i.p., daily.  Animals were injected for 6 
weeks prior to behavioral testing.  Daily injections continued throughout the testing 
period and all animals received injections 14 h before any behavioral testing to eliminate 
any acute effects of injection. Only one behavioral test was performed each day.  The 
behavioral experiments were conducted in the following order:  tail suspension test, 
forced swim test, open field test, and rotarod test. Approximately 24 h elapsed between 
each of the following tests. 
 
13-Cis-RA Plasma Level Determination 
After behavioral testing, blood samples were collected from treated animals 
immediately postmortem.  13-Cis-RA was administered to the mice approximately 16 h 
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before sacrifice.  To prevent retinoid degradation all steps were performed in the dark.  
The blood was allowed to coagulate for 30 min and then centrifuged at 1000 x g for 20 
min.  The plasma was then removed and stored at –80 ºC until the retinoid extraction was 
performed.  Samples were extracted as described (124).  In total, 0.7 volumes of 
acetonitrile:butanol (1:1) solution was added to the sample and vortexed for 45 s, then 0.6 
volumes of saturated K2HPO4 was added and vortexed for 10 s.  The samples were then 
centrifuged at 13,000 x g for 10 minutes.  The upper layer was removed and the sample 
volume brought up to 100 µL with 100% acetonitrile.  The absorbance of the samples 
was determined at 354 nm and 13-cis-RA concentration was determined by comparison 
to a standard curve.  For the standard curve, a known amount of 13-cis-RA was added to 
plasma from mice not treated with Accutane and extracted as described above.  All 
concentration values were corrected for initial and extracted sample volumes. 
 
Tail Suspension Test 
To perform the tail suspension test, animals were suspended by the tail on a 
horizontal beam 33 cm high.  Mice were taped to the bar using adhesive tape placed 
approximately 1 cm from the tip of the tail. A 6-min test period was used and videotaped 
for subsequent analysis.  The animals engaged in several escape-related behaviors 
interspersed with periods of immobility.  The duration of immobility was measured in 
seconds.  The mice were tested in a randomized, double-blinded manner.   
 
Porsolt Forced Swim Test 
The forced swim test is a pharmacologically validated model of depression-
related behavior in mice (125).  Mice were placed in a Plexiglas, cylindrical tank, 20 cm 
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x 51 cm, filled to a depth of 35 cm with room temperature water (25 + 0.5 ºC) for a total 
of 6 min and the test was videotaped for subsequent analysis.  Mice were scored for each 
of three behaviors: swimming, climbing, and immobility. Immobility was defined as the 
absence of escape-related behavior, such as swimming, climbing, or rearing.  Swimming 
behavior was assigned when the animal was moving around the container with all paws, 
while climbing behavior was assigned when the animal became vertical and clawed at the 
cylinder walls with its forepaws.  The duration of each of these behaviors was measured 
in seconds over a 6-min period.  The mice were tested in a randomized, double-blinded 
manner. 
 
Open Field Test 
The open field test was used to evaluate anxiety-related behaviors (126, 127).  
Animals were placed in a 16 x 16 cm open field apparatus (Med Associates, St Albans, 
VT).  Ambulatory and stereotypic activity was measured by infrared motion detectors 
spaced 2.5 cm apart.  Rearing and jumping activity was measured by another set of 
infrared motion detectors 4.6 cm above the floor.  The animal activity was monitored by 
Activity Monitor, version 5.10 (Med Associates, St Albans, VT) over the course of 5 
min.  The ambulatory time was determined in seconds for each minute spent in the open 
field as were the total ambulatory, vertical, and stereotypic times.  The percent of time the 
animal spent in the center (38% of the total field area) and the number of entries into the 
center of the field were also calculated.  Motor function was also assessed by considering 




In order to determine the effect of retinoids on motor coordination, the rotarod test 
was performed.  The rotarod test consisted of placing the animal on a rotating rod, 4 cm 
in diameter, 35 cm high (Columbia Instruments, Columbus, OH).  Low rotation speeds 
were chosen for this test since DBA/2J mice perform this task relatively poorly at higher 
speeds (128).  The animals were first placed on a rod rotating at 5 rpm for 2 min to 
acclimate to this novel motor task.  Each time an animal fell from the rod during this time 
period, the animal was placed back onto the rod.  After the 2-min acclimation period, the 
animal was allowed to rest for 1 min and then placed back on the rod rotating at 5 rpm.  
The latency to fall was then measured in seconds.  The animal was then placed on the rod 
for a second trial at a rotation speed of 10 rpm.  The latency to fall was again measured in 
seconds.  In all trials, if the mouse did not fall from the rod, it was removed from the rod 
after 2 min. 
 
Behavioral Evaluation and Statistical Analyses 
All behavioral tests were double-blinded and all were scored prior to decoding 
any of the tests.  Immobility data from the last four minutes of both the tail suspension 
and forced swim tests were analyzed with a 2 x 2 x 4 (Group x Test x Minute) repeated 
measures ANOVA, with the two tests and four minutes serving as repeated measures.  
We analyzed the two immobility tests in this way because they both examine the same 
construct (depressive behavior) using the same units of measurement (seconds of 
immobility).  This omnibus approach has been successfully applied to other behavioral 
measures meeting these criteria (129).  Only the last four minutes of each test were used 
in the analysis because of widespread zero values during the first 2 min of each test.  The 
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open-field and rotarod data were analyzed by two-tailed t-tests.  Values reported are 
mean + SEM of n = 12 observations unless otherwise indicated. 
 
RESULTS 
Confirmation of 13-Cis-RA plasma levels in treated mice 
The human dose of 13-cis-RA used to treat acne ranges from 0.5 to 2 mg/kg/d.  
The mice used in this study received an amount of 13-cis-RA within this range and 
identical to the amount administered to mice in the study by Crandall et al. (97).  The 
plasma level of 13-cis-RA in six mice chronically treated with 13-cis-RA was 1.5 + 0.4 
µg/mL.  This value is higher than that previously observed by Crandall et al. (97), 
potentially due to the use of different retinoid extraction techniques.  However, the 
plasma levels obtained in the present study are approximately twice that displayed by 
humans administered 0.5 mg/kg/d of 13-cis-RA, one-half the dose used in the present 
study.  Plasma 13-cis-RA concentrations in these patients reached 0.74 µg/mL (8) .  In 
addition, the plasma concentration obtained in the present study is similar to that reported 
in the Accutane capsules package insert were the peak plasma concentration of 13-cis-RA 
in healthy patients aged 12-15 years receiving multiple oral doses of 13-cis-RA for the 
treatment of severe acne ranged from 0.37 to 1.09 µg/mL.  Therefore, administration of 1 
mg/kg/d of 13-cis-RA to young, adult male mice results in plasma 13-cis-RA levels 
similar to those observed in human patients. 
 
13-Cis-RA Treatment Had No Effect on Weight Gain 
Weight gain over the six weeks of injections was followed to ensure that the 
animals were not showing overt signs of distress or discomfort.  Weekly weighing of the 
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mice showed that overall weight gain across the experiment was normal and that there 
was no difference in body weight between the 13-cis-RA treated group and the control 
group.  At the start of injections, the 13-cis-RA treated group weighed 15.5 + 0.4 g and 
the control group weighed 15.1 + 0.3 g.  At the beginning of the behavioral testing, the 
treatment group weighed 23.8 + 0.5 g and the control group weighed 23.1 + 0.5 g.  The 
behavioral tests had no effect on the weight of the animals. Daily monitoring confirmed 
that the animals were not showing any signs of distress as a result of the repeated 
injections, which were given on alternating sides of the abdominal cavity.  The injections 
were verified to be i.p. and not subcutaneous by feeling the skin on the underside of the 
animals daily for bubbles or scar tissue. 
 
Chronic Administration of 13-Cis-RA Increases Immobility in the Tail Suspension 
and Forced Swim Tests 
The effect of chronic administration of 13-cis-RA on young adult mouse behavior 
in the tail suspension (A and B) and forced swim (C and D) tests is shown in Figure 2.1.   
Both tests are pharmacologically validated models of behavioral despair in which the 
time spent immobile decreases with antidepressant treatment (43, 130).  The 2 x 2 x 4 
(Group x Test x Minute) repeated measures ANOVA of the immobility data showed no 
significant interactions and no significant effect of test, supporting the validity of 
analyzing the two tests in this way.  There was a significant main effect of group, F(1,21) 
= 4.8, p = 0.039, with 13-cis-RA treated mice showing significantly more immobility 
than vehicle controls. The estimated marginal means and standard errors for the two 
groups were 19 ± 2.1 s of immobility per min for the 13-cis-RA treated group and 12 ± 
2.0 s of immobility per min for the vehicle controls. The increase in immobility due to 
13-cis-RA treatment observed in the forced swim test appears to be due to a decrease in 
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swimming behavior (Fig. 2.1C).  There was no difference between the groups for the 
amount of time the animals spent engaged in climbing activity.  These data show that 
chronic 13-cis-RA administration increases immobility in both the tail suspension and 
forced swim tests, which is indicative of increased depression-related behavior. 
 
Chronic Administration of 13-Cis-RA has No Effect on Anxiety-related and Motor 
Behavior in the Open Field Test 
Approximately 25-50% of depressed youth also exhibit anxiety.  Selective 5-HT 
reuptake inhibitors have been used successfully to treat both depression and anxiety, 
potentially indicating a common etiology [For review see(131)].  Also, in mice, anxiety 
may be one factor that contributes to susceptibility to depression-related behaviors (132).  
The open field test is an anxiety-related behavioral paradigm that is sensitive to 
anxiolytic drugs (126, 127).  An animal exhibiting anxiety-related behavior will spend 
less time in the center of the open field.  There was no difference between the 13-cis-RA 
treated group and the control group in the number of entries into the inner zone of the 
field between the two groups (p = 0.61) (Fig. 2.2A).  13-Cis-RA treated mice made 21 + 
4 entries into the inner field and control animals made 24 + 2 entries. 
Retinoid signaling affects locomotion.  For example, RARβ–RXRβ, RARβ–
RXRγ and RXRβ–RXRγ double null mutant mice (but not the corresponding single 
mutants) exhibit reduced forward locomotion and rearing frequency in the open field test 
(34).  Also, retinoic acid-mediated effects have been implicated in Parkinson’s (133), and 
Huntington’s disease (134) [For review see (106)].  Therefore, to assure that the effects of 
13-cis-RA on behavior in the tail suspension and forced swim tests were due to a specific 
increase in despair-related behavior and not to an overall decrease in locomotion or 
coordination, we conducted the open field and rotarod tests, respectively.   There was no 
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difference in total ambulatory time (p = 0.68) or the ambulatory time in the inner zone of 
the field (p = 0.68) between the two groups (Fig. 2.2B).  The total ambulatory time of 
mice treated with 13-cis-RA was 55 + 3 seconds versus 57 + 2 seconds for the control 
mice.  The ambulatory time for the 13-cis-RA treated mice in the inner zone of the field 
was 7 + 1 seconds while control mice had 8 + 1 seconds of ambulatory time in the inner 
zone of the open field.  Additionally, there was no difference in the ambulatory distance 
traveled over the entire field (p = 0.78) or the inner zone of the field (p = 0.93) (Fig. 
2.1C).  13-Cis-RA treated mice traveled 1426 + 98 cm while control mice traveled 1451 
+ 57 cm over the entire field.  13-Cis-RA treated mice traveled 211 + 30 cm in the inner 
zone and the control mice traveled 216 + 19 cm.  Because 13-cis-RA treatment did not 
alter the number of entries into, or the total distance traveled in, the center zone of the 
open field it is unlikely that 13-cis-RA has an effect on anxiety-related behavior.  The 
lack of a difference between groups with respect to total distance traveled or total 
ambulatory time indicates that 13-cis-RA has no effect on overall locomotion compared 
with vehicle treated controls. 
 
Chronic 13-Cis-RA Administration Increases Motor Coordination on the Rotarod 
There was no impairment of motor coordination in mice treated with 13-cis-RA 
(Fig. 2.3).  There was a trend for mice treated with 13-cis-RA to remain on the rotating 
rod longer than control mice when tested at a rotational speed of 5 rpm (p = 0.07).  Mice 
administered 13-cis-RA were able to stay on the rod for 105 + 10 seconds, whereas 
control mice were only able to remain on the rod for 75 + 13 seconds.  However, when 
tested at 10 rpm, there was no difference between the latency to fall time for the treated 
and control mice (p = 0.91).  Retinoids have been implicated in the regulation of 
locomotion because RARβ-RXRβ, RARβ-RXRγ, and RXRβ-RXRγ double null mutant 
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mice were shown to have locomotor deficits (34).  In contrast, chronic 13-cis-RA 
treatment tends to improve motor coordination at low rotational speeds in the rotarod test 
without an effect on total locomotion (Fig. 2.3). 
 
DISCUSSION 
Here we demonstrate that chronic administration of 13-cis-RA to young adult 
male mice increased the time spent immobile in both the tail suspension and forced swim 
tests.  In the open field test there was no evidence of a change in anxiety-related behavior.  
Furthermore, there was no impairment of locomotion or motor coordination in 13-cis-RA 
treated animals.  Taken together these data indicate that the increased immobility in 
behavioral despair paradigms is not due to an effect on motor systems, but results from 
increased depression-related behavior.   
Increased immobility in the forced swim test has been reported to occur in 
situations that increase vulnerability to depression such as estradiol deficiency due to 
aromatase knockout (45), stress due to food restriction (46), magnesium depletion (47), 
and choline administration (48).  The behavior of the animals in the tail suspension test 
was not assessed in these studies.  However, increased immobility in both the forced 
swim and tail suspension tests does occur due to the pro-depressant effects of withdrawal 
from chronic amphetamine administration (49), centrally administered urotensin-II (50), 
and interleukin-1 and endotoxin injection (51).  Interestingly, in the forced swim test, 
antidepressants that target the serotonergic system increase swimming behavior, thereby 
decreasing immobility (135). On the other hand, antidepressants that target noradrenergic 
systems increase climbing behavior.  In our experiments, 13-cis-RA treatment leads to an 
increased immobility with a concomitant decrease in swimming behavior, without an 
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effect on climbing behavior.  This may indicate that chronic 13-cis-RA administration 
disrupts serotonergic systems, leading to increased depression-related behavior.  
A recent study reported the effects of chronic 13-cis-RA administration on adult 
rats.  In the forced swim test, Ferguson et al. (98) reported a marginally significant effect 
of 13-cis-RA treatment on immobility.  However, in contrast to our observations, these 
authors observed less immobility following 13-cis-RA administration. This reduced 
immobility was observed for a successive two-day test in which the immobility for the 
second day was found to be decreased for all test groups.  The fact that immobility was 
decreased on the second test day is surprising because the forced swim test, when 
conducted on consecutive days, generally results in increased immobility each day 
regardless of treatment [for example (136)].  In addition, Ferguson et al. (99) reported 
that there was no change in voluntary saccharin solution intake in treated rats, reflecting 
an absence of the depressive symptom anhedonia.  The authors concluded that 13-cis-RA 
did not severely affect depression-like behaviors in male or female rats.   
There are three important differences between our study and that of Ferguson et 
al. (98): 1) age and species of test subjects, 2) method of dosing, and 3) dose of drug 
administered.  The adolescent mice used in our study are at a much earlier stage of 
development than the adult rats used by Ferguson et al. (98); we began dosing between 
the time of weaning and the onset of sexual maturity. The dose of 13-cis-RA we 
administered was 1mg/kg via i.p. injection in comparison to the much higher doses (7.5 
and 22.5 mg/kg) used by Ferguson et al. (98) administered by oral gavage.  The dose we 
used is within the recommended range for treatment of patients (0.5-2.0 mg/kg/day) and 
we achieved serum levels in treated mice that were equivalent to those seen in patients.  
Repeated drug administration is a potential stressor and stress has been shown to 
influence depression-related behavior (137).  Ferguson et al. (98) also examined behavior 
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in the open field and in one treatment group saw that 13-cis-RA treated rats were 
significantly less active than same sex controls.  This increase in freezing time in the 
open field increased with the duration of treatment even in control animals.  One 
explanation for this is that all animals were exhibiting enhanced stress-responses, which 
can manifest as increased freezing time in the open field test.  It is therefore possible that 
Ferguson et al. (98) were not able to detect changes in depression-related behaviors in 13-
cis-RA treated animals because they were masked by elevated stress in all treatment 
groups. 
Changes in adult behavior as a result of 13-cis-RA administration are perhaps not 
surprising given the evidence linking retinoid signaling to adult CNS function (105, 106).  
A large number of neuronal genes have been shown to be retinoid-responsive (106), but it 
is not yet known whether 13-cis-RA can regulate gene transcription in the adult brain.  
13-Cis-RA could be activating gene transcription by either isomerizing to ATRA and 
binding to the RAR (9) or directly binding to the RAR itself (10).  Although 13-cis-RA 
binds to the RAR with much lower affinity than ATRA, once bound to the RAR, 13-cis-
RA is very efficient at initiating transcription (10).  Given that depression is a complex, 
multifactorial phenomenon involving dopaminergic, serotonergic, noradrenergic and 
other transmitter pathways, altered regulation of a subset of target genes by 13-cis-RA 
could produce subtle changes in neuronal function that lead to enhanced depression-
related behaviors.  For example, a verified RARE has been found in the promoter region 
of the dopamine D2 receptor and all-trans-retinoic acid can upregulate dopamine D2 
receptor expression (24).  Increased dopamine D2 receptor abundance has been reported 
in patients with major depression (138).  Similarly, the 5-hydroxytryptamine 1A (5-HT1A) 
receptor, which has a role in regulating the firing of 5-HT neurons and is associated with 
depression-related personality traits (139), has been shown to be upregulated in response 
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to all-trans-retinoic acid treatment in neuronal cells (140).  Altered regulation of either 
the D2 receptor or the 5-HT1A receptor genes by 13-cis-RA, as well as other neuronal 
genes, could provide a possible mechanism for the changes in depression-related 
behaviors seen in chronically treated mice.   
An alternative mechanism by which 13-cis-RA could alter depression-related 
behaviors is by affecting adult neurogenesis. In animal models, inescapable stress reduces 
hippocampal neurogenesis, a phenomena that can be reversed with antidepressant 
treatment (141).  Apart from the well documented effects of retinoids on neuronal 
differentiation during development (142), retinoid signalling has been shown to promote 
adult neurogenesis in the hippocampus and olfactory bulb (143, 144).  A role for retinoids 
in learning and memory behaviors had previously been established using RAR knockout 
mice and vitamin A deficient models [for review see (145)].  Interestingly, both RARβ or 
RARβ-RXRγ double null mutant mice and vitamin A deficiency are associated with 
deficits in spatial learning and memory (121, 146, 147).  In contrast, long-term 
administration of 13-cis-RA suppresses hippocampal neurogenesis and decreases 
hippocampal cell survival (97).  It may seem contradictory that RARβ and RARβ/RXRγ 
null mice have decreased spatial learning while chronic administration of 1 mg/kg/day of 
ATRA or 13-cis-RA to adolescent male CD1 mice also impairs learning and memory, but 
this may be a case where the dose makes the poison.  Although physiological levels of 
retinoids and retinoid signaling pathways are required for neuronal differentiation and 
ultimately, learning and memory, pharmacological levels of retinoids may initiate other 
processes that inhibit neurogenesis.  Thus, the ability of 13-cis-RA to increase 
depression-related behavior in the present study may be due to decreased hippocampal 
neurogenesis and cell survival and likely involves altered regulation of neuronal gene 
expression.  Interestingly, adult neurogenesis requires functional serotonergic signaling 
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(148, 149), further suggesting that 13-cis-RA mediates its effects by specifically 
regulating serotonergic gene expression and/or hippocampal neurogenesis.   
13-Cis-RA is an effective treatment for severe recalcitrant acne (150).  
Diagnosing depressive symptoms in acne patients following 13-cis-RA treatment is 
complicated by the psychological effects of severe acne itself.  Clinically significant 
anxiety and depression symptoms have been reported in both adolescents and adults with 
chronic acne (101, 151).  Additionally, adolescents under social stress may be on the 
border of clinical depression and 13-cis-RA treatment may be a precipitating event (152).  
Despite the possible confounding effects of existing conditions, there are some instances 
where patients with no previous history of psychiatric symptoms develop depression and 
suicidal ideation following 13-cis-RA treatment (7).  Use of a mouse model allowed us to 
examine the effects of 13-cis-RA on depression-related behaviors independent of pre-
existing conditions, self-image, and other factors that confound human studies.  This 
report is the first to demonstrate that 13-cis-RA administration enhances depression-
related behaviors in mice.  These depression-related behaviors may be due to changes in 
brain metabolism, altered hippocampal neurogenesis, and altered serotonergic function. 
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Figure 2.1:  13-Cis-RA increases immobility in the tail suspension and forced swim tests. 
Total time spent immobile in the tail suspension (A) and forced swim (C) tests are 
expressed as the mean + SEM for the last four minutes of the observation period.   The 
development of immobility during the tail suspension (B) and forced swim (D) tests are 
shown as mean + SEM seconds per each minute of the six minute observation period.  
Overall immobility time from both tests (as assessed by repeated measures ANOVA) 
showed a significant main effect of group, F(1,21) = 4.8, p = .039, with 13-cis-RA treated 
mice showing significantly more immobility than vehicle controls.  n = 11 13-cis-RA 




Figure 2.2: 13-Cis-RA does not affect performance in the open field test. 
The number of entries into the center (A), the total ambulatory time (B) and the total 
ambulatory distance (C) measured during a five minute observation period in the open 
field test.  In each case there was no difference between 13-cis-RA treated mice and 
vehicle treated controls.  Values are mean + SEM with n = 12 for each group. 
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Figure 2.3: 13-Cis-RA does not impair motor performance in the rotarod test. 
The mean latency to fall from a rod rotating at 5 rpm or at 10 rpm is shown during a two-
minute test period.  The 13-cis-RA treated mice tended to remain on the rotarod longer at 
5 rpm.  Treatment had no effect on rotarod performance at 10 rpm.  Values are mean + 
SEM with n = 12 for each group. 
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Chapter 3: 13-Cis-RA Alters Intracellular Serotonin, Increases 5-HT1A 
Receptor and Serotonin Reuptake Transporter Levels In Vitro 
ABSTRACT 
As shown in chapter 2, chronic administration of 13-cis-RA to adolescent male 
mice increased depression-related behaviors.  Here, we have examined whether 13-cis-
RA regulates components involved in serotonergic neurotransmission in vitro.  We used 
the RN46A-B14 cell line, derived from rat embryonic raphe nuclei.  This cell line 
synthesizes serotonin (5hydroxytryptamine, 5-HT) and expresses the 5-HT1A receptor and 
the serotonin reuptake transporter (SERT).  Cells were treated with 0, 2.5, or 10 µM 13-
cis-RA for 48 or 96 h and the levels of 5-HT, its metabolite 5-hydroxyindoleacetic acid 
(5-HIAA), 5-HT1A receptor and SERT determined.  Treatment with 13-cis-RA for 96 h 
increased the intracellular levels of 5-HT and tended to increase intracellular 5-HIAA 
levels.  Furthermore, 48 h of treatment with 2.5 and 10 µM 13-cis-RA significantly 
increased 5-HT1A protein to 168.5 ± 20.0 and 148.7 ± 2.2 % of control respectively.  
SERT protein levels were significantly increased to 142.5 ± 11.1 and 119.2 ± 3.6 % of 
control by 48 h of treatment with 2.5 and 10 µM of 13-cis-RA respectively.  Increases in 
both 5-HT1A receptor and SERT proteins may lead to decreased 5-HT availability at 
synapses. Such an effect of 13-cis-RA could contribute to the increased depression-
related behaviors we have shown in mice. 
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INTRODUCTION 
The Serotonergic System 
5-HT (serotonin) is a monoamine neurotransmitter in the brain and 
gastrointestinal tract.  5-HT is also present in the blood and was discovered in 1948 and 
named for its role in vascular tone, “sero” for serum and “tonin” for tone.  5-HT is 
produced from tryptophan in a two-step process (Fig. 3.1).  Tryptophan is first converted 
to 5-hydroxytryptophan by the rate limiting enzyme tryptophan hydroxylase.  5-
Hydroxytryptophan is then converted to 5-hydroxytryptamine, or 5-HT, by the enzyme 5-
HTP decarboxylase.  5-HT is then broken down to its inactive catabolite, 5-
hydroxyindole acetic acid (5-HIAA), by monoamine oxidase A (MAOA).  Intracellular 
levels of 5-HT are controlled by 5-HT synthesis from tryptophan, 5-HT degradation to 5-
hydroxyindole acetic acid (5-HIAA), vesicular packaging and release of 5-HT into the 
synapse, and reuptake of 5-HT into the cell by serotonin reuptake transporter (SERT or 5-
HTT) (Fig. 3.1).  An additional regulator of 5-HT release is the somatodendritic serotonin 
receptor 1A (5-HT1A) (Fig. 3.1).  This autoreceptor is activated by 5-HT to inhibit firing 
of serotonergic raphe neurons (153). 
The raphe nuclei are the main 5-HT producing cells in the central nervous system 
and the raphe nuclei and have processes that project widely throughout the brain.  The 
processes of the dorsal raphe nuclei innervate, inter alia, the frontal cortex, the lateral 
septum and the ventral tegmental area (154).  The median raphe nuclei project to the 
lateral habenula and the interpeduncular nucleus (155), among other regions of the brain.  
The hypothalamus and the septum receive input from both the dorsal and median raphe 
nuclei (154, 155) and the dorsal and median raphe nuclei send processes to each other 
(154, 155).  Additionally, the molecular layer of the hippocampus receives input from 
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dorsal raphe nuclei while the hilus of the dentate gyrus receives input from the median 
raphe nuclei (148).  
The 5-HT1A receptor is a presynaptic autoreceptor found predominately in the 
raphe nuclei and a postsynaptic receptor found in the hippocampus, prefrontal cortex and 
caudate of the forebrain (156, 157).  This metabotropic receptor is inhibitory in both the 
presynaptic and postsynaptic neurons of serotonergic circuits.  The 5-HT1A receptor is a 
G-protein coupled receptor that inhibits adenylate cyclase activity in postsynaptic 
neurons.  However, in presynaptic neurons it is thought to activate an inwardly rectifying 
potassium channel (156).  The inhibition of raphe nuclei neuron firing due to activation 
of the 5-HT1A receptor directly inhibits neurotransmitter release [Reviewed in (158)]. 
The SERT is responsible for removing 5-HT from the synaptic cleft to terminate 
5-HT signaling.  SERT uses co-transport of sodium and chloride ions as a driving force 
for 5-HT transport into the cell [Reviewed in (159)].  The electrochemical gradient that 
drives sodium and chloride ions into the cell facilitates 5-HT transport, while the 
movement of potassium ions out of the cell through the transporter is what renders it 
competent for the next cycle of 5-HT transport [Reviewed in (159)].  Thus, SERTs are 
activated when the cell is hyperpolarized.  Therefore inhibitory effects mediated by the 5-
HT1A receptor not only inhibit 5-HT release, but also enhance the reuptake of 5-HT from 
the synaptic cleft (156). 
 
Serotonin and Depression 
Although the etiology of depression is still unknown, the serotonergic system has 
long been a target of antidepressant drugs (160).  5-HT was discovered to have a role in 
the pathogenesis of depression in the 1950s when an antidepressant response was noticed 
in tuberculosis patients taking iproniazide (a monoamine oxidase inhibitor, or MAOI) and 
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imipramine (a selective serotonin reuptake transporter inhibitor, or SSRI) [Reviewed in 
(161)].  5-HT reuptake and metabolism are targets of antidepressants, with the net result 
being increased levels of 5-HT in the synaptic cleft (Fig. 3.1).  SERT inhibitors block the 
transport of 5-HT into the cell from the synaptic cleft while MAOA inhibitors block the 
metabolism of 5-HT to its inactive catabolite 5-HIAA.  The role of 5-HT in human 
depression is further supported by studies showing reduced 5-HIAA levels in the 
cerebrospinal fluid (162) and polymorphisms in 5-HT1A receptor (163) and SERT (164, 
165). 
Evidence is accumulating that suggests the role of the 5-HT1A receptor in 
regulating mood disorders.  For example, altered expression of and polymorphisms in the 
5-HT1A receptor are implicated in depression [Reviewed in (166)] and 5-HT1A receptor 
levels are increased in the midbrain of suicide victims with major depression (163).   
Chronic antidepressant treatment reduces the electrophysiological response to 5-HT1A 
autoreceptors (162, 167) disinhibiting the action potential firing of the raphe nuclei and 
enhancing serotonergic neurotransmission (167) 
Altered expression of the SERT is also implicated in depression [Reviewed in 
(166)] and regulation dysfunction of SERT has been associated with neuropsychiatric 
disorders and psychological traits such as bipolar disorder, anxiety, obsessive compulsive 
disorder, schizophrenia, and eating disorders (168).   
Both the 5-HT1A null mouse and the SERT knockout mouse exhibit decreased 
immobility time in the tail suspension test ((169) and (170) respectively).  In contrast, the 
SERT knockout mouse has increased immobility in the forced swim test (170).  SERT 
knockout mice also display significant impairment in shock avoidance (170) and 
treatment of mice between postnatal days 4 and 21 via i.p. injection with fluoxetine to 
block SERT activity replicated the impairment in shock avoidance seen in SERT 
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knockout mice even though testing was done nine weeks after the last fluoxetine injection 
(171).  Perhaps the increased immobility in the forced swim test exhibited by SERT 
knockout mice is due to abnormal development of serotonergic signaling circuits in early 
life. 
 
Retinoid Signaling and Depression-Related Behaviors 
All-trans-retinoic acid (ATRA) is the endogenous ligand for retinoic acid 
receptors (RAR) and is synthesized from dietary vitamin A (retinol) (172).  13-Cis-RA is 
a synthetic retinoid capable of either binding to RAR itself (10) or being isomerized to 
ATRA prior to RAR binding (9).  RAR heterodimerize with retinoid X receptors (RXR) 
and together they bind to specific DNA sequences termed retinoic acid response elements 
(RARE) (172).  Binding of ligand to the RAR initiates transcription (172) and this has led 
to the view that retinoids are primarily regulators of gene transcription, either directly or 
via intermediate genes.  The expression of many neuronal genes is affected by ATRA and 
a few have been reported to have functional RARE suggesting that retinoids act as 
transcriptional regulators in neuronal cells [for review see (106)].  However, retinoids can 
also influence cellular function by altering protein levels via non-transcriptional 
mechanisms, such as increasing mRNA (14, 15) or protein stability (16). 
As shown in chapter 2, 13-cis-RA administration increases depression-related 
behaviors in mice (173).  Adolescent, DBA/2J mice treated with 1 mg/kg/d of 13-cis-RA, 
the same dose prescribed to human patients, exhibited significantly more immobility than 
vehicle-treated controls in both the tail suspension test and the forced swim test (173).  
Further analysis of data in the forced swim test reveals that the increase in immobility is 
accompanied by a decrease in swimming, but not climbing behavior (173).  For rodents, 
in the forced swim test, antidepressants that target the serotonergic system decrease 
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immobility due to an increase in swimming time (135).  In contrast, antidepressants that 
target the noradrenergic system, decrease immobility and increase time spent climbing 
(135).   
The ability of 13-cis-RA to cause depression-related behavior in adolescent mice 
led us to hypothesize that serotonergic function may be altered in the raphe nuclei in 
response to 13-cis-RA treatment.  In this study we used a cell line derived from rat raphe 
nuclei, RN46A-B14, as our model.  These cells are serotonergic and express the 5-HT1A 
receptor and SERT (174, 175).  We show that treatment of RN46A-B14 cells with 13-cis-
RA increases intracellular 5-HT content. Intracellular 5-HIAA content also tends to be 
increased.  In addition, both the 5-HT1A receptor and SERT are increased following 13-




The in vitro studies were performed in the RN46A-B14 cell line.  The RN46A 
parent cell line was derived from medullary raphe nuclei of an embryonic day 13 rat and 
immortalized with the temperature sensitive mutant of the SV40 large T-antigen.  At the 
permissive temperature of 33˚C, the cells are prolific.  Although these cells are from the 
raphe nuclei, they are not serotonergic until they undergo a differentiation process.  To 
differentiate these cells, they are shifted to 39˚C and grown in a low serum medium.  
These cells require the addition of brain derived neutrophic factor (BDNF) for the 
duration of their differentiation process in order to become serotonergic (176), thus the 
RN46A parent cell line was transfected with the human clone of the BDNF gene and the 
RN46A-B14 cell line derived to constitutively expresses BDNF (174).  An additional part 
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of the differentiation process is the addition of 40 mM KCl to the growth media four days 
after the temperature shift occurs.  This depolarizing condition is continued throughout 
the duration of the experiment.  Although the RN46A-B14 cell line expresses TPH, the 
addition of 40 mM KCl is required for TPH phosphorylation, and thus activation of the 
enzyme (176).  Without the addition of 40 mM KCl, the cells do not produce very large 
amounts of 5-HT, even if exposed to the higher temperature and BDNF (176).  The cells 
used for all of the in vitro studies were differentiated as described here prior to treatment 
with retinoids.  
RN46A-B14 cells (a gift from Dr. Scott Whittemore, University of Louisville, 
Louisville, KY) were used to investigate the effects of 13-cis-RA on components of the 
serotonergic system.  RN46A-B14 cells were maintained in DMEM/F12 medium 
containing 10% FBS and antibiotics (1,000 units/mL penicillin and 1,000 µg/mL 
streptomycin) at 33°C.  Prior to differentiation, cells were plated at a density of 4 x 106 
cells/plate in 100 mm dishes and allowed to grow for 2-3 d until reaching approximately 
70% confluency.  Cells were differentiated as described (174) by incubation at 39°C in 
DMEM/F12 medium containing 1% FBS, antibiotics (1,000 units/mL penicillin and 
1,000 µg/mL streptomycin), 5 µg/mL insulin, 20 nM progesterone, 100 µM putrescine, 1 
µg/mL transferrin, and 1% ovalbumin (w/v).  Media was changed every d for the first 4 d 
and on d 4, 40 mM KCl was added.  Depolarization with KCl enhances the serotonergic 
phenotype of these cells (175, 176).  Media was then changed every 48 h and contained 
40 mM KCl for the duration of the experiment.  After 8 d at 39°C, differentiated cells 
were treated with 0, 2.5, or 10 µM 13-cis-RA dissolved in ethanol vehicle for 48 or 96 h.  
The Accutane package insert reports that the steady state plasma concentration of 13-cis-
RA ranges from a minimum (mean ± SD) of 352.32 ± 184.44 ng/mL (1.2 µM) to a 
maximum of 731.98 ± 361.86 ng/mL (2.5 µM) (6).  Thus, the 2.5 µM concentration of 
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13-cis-RA was chosen to reflect the average steady state concentration of 13-cis-RA and 
the 10 µM concentration of 13-cis-RA may be reached soon after 13-cis-RA 
administration.  All cells, including control, were treated with an equal amount of 
vehicle.  All retinoid manipulations were performed under subdued light.  
 
HPLC Analysis of Intracellular 5-HT and 5-HIAA Content 
Isocratic high performance liquid chromatography (HPLC) with electrochemical 
detection was used to examine the effect of 13-cis-RA on 5-HT production in RN46A-
B14 cells.  Cells were grown and differentiated as described above.  Although the media 
contained 66 µM tryptophan, to ensure adequate levels of 5-HT for detection by HPLC 
analysis, after 48 or 96 h of 13-cis-RA treatment, cells were incubated with 10 µM 
tryptophan and 10 µM chlorgyline for 30 min and then with 10 µM fluoxetine for an 
additional 30 min as described (175).  Tryptophan is the precursor for 5-HT synthesis, 
chlorgyline inhibits monoamine oxidase A and fluoxetine blocks SERT and therefore 5-
HT entry into the cell, thereby allowing for detection of 5-HT.  Cells were left attached to 
the plate and washed 2X with phosphate buffered saline (PBS) and lysed by freezing at -
80°C.  The next day, 200 µL of e-pure water was added to the plate, the plate was scraped 
and the lysed cells harvested, transferred to an eppendorf tube, and centrifuged at 13,000 
x g for 10 min.  The supernatant was stored at -20°C until analysis.  The protein content 
of each sample was determined using a portion of the supernatant and the BioRad DC 
protein assay kit (Hercules, CA).   
5-HT and 5-hydroxyindoleacetic acid (5-HIAA) levels in the lysate were 
determined in the College of Pharmacy Analytical Instrumentation Facility Core 
(University of Texas at Austin, Austin, TX) by HPLC electrochemical method modified 
from (177).  Briefly, the samples (60 to 100 µL) were injected into the HPLC system 
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which consisted of a Shimadzu SCL-10A system controller and a LC-10AD pump 
equipped with a SIL-10A auto-sampler (Shimadzu, Columbia, MD), coupled to a four-
channel CoulArray electrochemical detector (ESA, Chlemsford, MA).  The isocratic 
mobile phase consisted of 4 mM citrate, 8 mM ammonium acetate, 20 mg/L EDTA, and 
120 µM 1-octanesulfonic acid sodium salt (SOS), pH 3.5, and 5% methanol.  5-HT and 
5-HIAA were separated by a 4.6 x 80 mm reverse phase HR-80, 3 µm particle size, 
120Å, column (ESA Biosciences Inc., Chelmsford, MA) at a flow rate of 1 mL/min and 
analyzed by electrochemical detection using a CoulArray electrochemical detector (ESA 
Biosciences Inc., Chelmsford, MA).  The potential of channels one through four of the 
CoulArray were set at -50, 0, 300, and 400 mV respectively (Fig. 3.2A).  Peak area (nC) 
of 5-HT or 5-HIAA at the corresponding retention time on the chromatogram resulting 
from 300 mV was obtained using CoulArray for Windows, version 1.12 software (ESA, 
Chlemsford, MA).  The peak area was used to quantify the 5-HT or 5-HIAA in each 
sample injected, based on the standard curve.  The total 5-HT or 5-HIAA concentration 
was corrected for sample volume loaded and normalized to protein content. 
 
Northern Blot Analysis of 5-HT1A and SERT mRNA 
For probe generation, total RNA was isolated from differentiated vehicle control-
treated RN46A-B14 cells or adult rat hippocampus with RNA Stat-60 (Tel-Test, 
Friendswood, TX).  Two µg of RN46A-B14 or rat hippocampal total RNA were reverse-
transcribed with oligo-dT primers and the Reverse Transcription System (Promega, 
Madison, WI) as per manufacturer’s instructions.  Amplification of the 5-HT1A and 
GAPDH cDNA were performed using RN46A-B14 cDNA and the following primers:  5-
HT1A forward primer: 5’- AGC ATC TCC GAC GTG ACC TTC AGC TAC CA -3’ 
reverse primer, 5’- GCT CCC TTC TTT TCC ACC TTC CTG ACA GT -3’, resulting in 
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a 635-bp product (178).  GAPDH forward primer: 5’- CGT CTT CAC CAC CAT GGA 
GA -3’ reverse primer, 5’- CGG CCA TCA CGC CAC AGT TT -3’, resulting in a 260-
bp product (179).  Amplification of SERT cDNA was performed using hippocampal 
cDNA and the following primers.  SERT forward primer: 5’- TGA CCA GCA GCA 
TGG AGA CC -3’ reverse primer: 5’- CCA CGG CAT AGC CAA TGA C -3’, resulting 
in a 304 bp product (180).  5-HT1A, GAPDH, and SERT cDNA were amplified using Taq 
polymerase (New England Biolabs Inc. Ipswich, MA) as per manufacturer’s instructions 
under the following PCR conditions:  95°C for 5 min followed by 50 cycles of 95°C for 
30 sec, 60°C for 30 sec, and 72°C for 30 seconds, with a final extension period of 7 min 
at 72°C.  PCR reactions were then electrophoresed in a 1.8% agarose gel and products of 
the appropriate size were purified using the Qiagen Gel Extraction kit (Qiagen, Valencia, 
CA) as per the manufacturer’s instructions.  All products were sequenced to confirm their 
identity.  
Total RNA was isolated from cells differentiated and treated with 0, 2.5, or 10 
µM 13-cis-RA for 48 or 96 h as described above using RNA Stat-60 (Tel-Test, 
Friendswood, TX).  RNA was electrophoresed through 1.2% agarose/2.2 M formamide 
gels, transferred to nylon filters, and cross-linked to the filters with a UV-Stratalinker 
(Stratagene) as described (124).  The cDNA probes for 5-HT1A, SERT, and GAPDH were 
labeled with [α-32P]dCTP using the Random Primed DNA Labeling Kit (Roche Applied 
Science, Indianapolis, IN) as per the manufacturer’s instructions.  Membranes were 
prehybridized overnight at 42°C in hybridization solution [50% (w/v) deionized 
formamide/0.2% BSA/0.2% polyvinyl pyrrolidone/2% Ficoll (molecular weight 400,000 
g/mol)/50 mM Tris·HCl, pH 7.5/0.1% sodium pyrophosphate/1% SDS/10% dextran 
sulfate/100 µg/ml salmon sperm DNA] and then hybridized overnight at 42°C in 
hybridization solution containing radiolabled probe. After hybridization, the membranes 
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were washed and processed as described previously (124).  The membranes were then 
exposed to film for 24 h.  All membranes were stripped and re-hybridized with GAPDH 
to control for loading differences.  Autoradiographs were quantitated using a BioRad Gel 
Documentation System (Hercules, CA). 
 
Western Blot Analysis of 5-HT1A and SERT Protein 
The effect of 13-cis-RA on 5-HT1A and SERT protein levels in serotonergic cells 
was examined using semi-quantitative western blot analysis. RN46A-B14 cells were 
differentiated as described above and treated with 13-cis-RA for 48 or 96 h.  For 5-HT1A 
and SERT analysis, cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% 
deoxycholate, 0.1% SDS, 50 mM Tris, 1 mg/ml leupeptin, 1 mM DTT, 2 mM NaOV4, 1 
mg/ml PMSF, 1 mg/ml trypsin inhibitor, and 10 mM aprotinin) and equal amounts of 
protein (50 µg for 5-HT1A or 75 µg for SERT) were electrophoresed on 12% (5-HT1A) or 
10% (SERT) SDS-PAGE gels.  Protein was quantitated using BioRad DC protein assay 
kit (Hercules, CA).  After electrophoresis, protein was transferred to a nitrocellulose 
membrane.     
For analysis of 5-HT1A levels, the blots were prehybridized with 5% milk in TBST 
(10 mM Tris, pH 8, 150 mM NaCl, and 0.5% Tween-20) for 1 h at room temperature 
before overnight incubation at 4°C with 5-HT1A polyclonal antibody (catalogue #sc-
10801, Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a 1:300 dilution.  For analysis 
of SERT levels, blots were prehybridized 5% milk in TBST prior to incubation with a 
1:200 dilution of polyclonal anti-SERT antibody (catalogue #sc-1458, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) in 1% BSA in TBST at 4°C overnight.  Secondary 
antibodies were goat anti-rabbit (catalogue #0031460, Pierce, Rockford, Il) or bovine 
anti-goat (catalogue #sc-2350, Santa Cruz Biotechnology Inc., Santa Cruz, CA), for 5-
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HT1A or SERT respectively, and were incubated in 5% milk for one hour at room 
temperature.   Immunoreactivity was detected using the Horseradish Peroxidase Super 
Signal West Pico Chemiluminescent Substrate kit (Pierce, Rockford, IL).  The 
membranes were then stripped and re-probed with polyclonal β-actin antibody (catalogue 
#A2066 Sigma, St. Louis, MO) at a 1:10,000 dilution to control for differences in 
loading.  Densitometry was performed using a BioRad Gel Documentation System 
(Hercules, CA). 
 
RT-PCR analysis of RAR/RXR expression 
RN46A-B14 cells were grown and differentiated for eight days as described, and 
on the eighth day, total RNA was extracted from RN46A-B14 cells as described above.  
DNA was removed by DNase digestion and total RNA (1 µg) was reverse-transcribed 
with oligo-dT primers and the Reverse Transcription System (Promega, Madison, WI) as 
per manufacturer’s instructions.  cDNA was then subjected to 40 PCR cycles, Tm = 60 
°C, with the primers listed below.  For adult rat dorsal raphe tissue, total RNA was 
extracted using Trizol reagent (Invitrogen, Carlsbad, CA).  DNA was removed by means 
of a DNase digest and total RNA (0.25µg) was reverse-transcribed using RT/ Platinum® 
Taq Mix (Superscript™ One-Step RT-PCR with Platinum® Taq, Invitrogen, Carlsbad, 
CA) as per manufacturer’s instructions, with the gene specific primers listed.  
Amplification of RARα, RARβ, RARγ, RXRα and RXRβ/γ cDNA were achieved using 
the following primers: RARα forward: 5’- CTG GAG ATG GAC GAT GCT GAG ACT 
-3’ reverse: 5’- CAC AGA TGA GGC AGA TGG CAC TGA -3’ resulting in a 54-bp 
product (181); RARβ forward: 5’- CAA AGC CTG CCT CAG TGG ATT CA -3’ 
reverse: 5’- AGT GGT AGC CCG ATG ACT TGT CCT -3’ resulting in a 178-bp 
product (181); RARγ forward: 5’- GGA ACT CAT CAC CAA GGT CAG CAA -3’ 
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reverse: 5’- CGC TTC GCA AAC TCC ACA ATC TT -3’ resulting in a 175-bp product 
(181); RXRα forward: 5’- CTT TGA CAG GGT GCT AAC AGA GC -3’ reverse: 5’- 
ACG CTT CTA GTG ACG CAT ACA CC -3’ resulting in a 172-bp product (182); 
RXRβ/γ forward: 5’- AGG CAG GTT TGC CAA GCT TCT G -3’ reverse: 5’- GGA 
GTG TCT CCA ATG AGC TTG A -3’ resulting in a 102-bp product (183). 
 
Statistical Analyses 
Statistical analyses were performed using Excel (XP 2002; Microsoft).  Two-
tailed, Student’s t-tests were performed to test for differences between vehicle control 
and 13-cis-RA treatments.  Data are expressed as mean ± SEM, n = 3, unless otherwise 
indicated, and differences were considered significant at p < 0.05. 
 
RESULTS 
Effect of 13-Cis-RA Treatment on Intracellular 5-HT and 5-HIAA Levels  
HPLC was used to determine the effect of 13-cis-RA treatment on intracellular 5-
HT levels in RN46A-B14 cells.  The levels of 5-HIAA, the primary metabolite of 5-HT, 
were also determined.  5-HT and 5-HIAA peak retention times reflect their respective 
standards at 300 mV (Fig. 3.2A and B).  We found that 48 h of 2.5 µM 13-cis-RA 
treatment did not increase intracellular 5-HT (Fig. 3.2C) or 5-HIAA (Fig. 3.2D) levels in 
RN46A-B14 cells.  However, treatment with 10 µM 13-cis-RA for 48 h decreased (p = 
0.01) intracellular 5-HT levels to 77.8 ± 6.2% of control (Fig. 3.2C), but had no effect on 
5-HIAA (Fig. 3.2D).  Extending treatment for 96 h with 10 µM 13-cis-RA significantly 
increased the intracellular 5-HT concentration to 206.9 ± 37.1% of vehicle control  (p = 
0.03) (Fig. 3.2C).  Both 2.5 and 10 µM 13-cis-RA tended to increase intracellular 5-
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HIAA levels to 132.4 ± 18.8% (p = 0.14) and 181.7 ± 38.1% of vehicle control (p = 
0.07), respectively, after 96 h of treatment (Fig. 3.2D).  These data indicate that 
prolonged treatment of RN46A-B14 cells with 13-cis-RA tends to increase intracellular 
5-HT and 5-HIAA content. 
 
Effect of 13-Cis-RA Treatment on 5-HT1A mRNA and Protein Levels 
Because retinoids are well known for their ability to induce gene transcription 
(172), northern blot analysis was used to examine the effect of 13-cis-RA on 5-HT1A 
mRNA levels in RN46A-B14 cells. 13-Cis-RA treatment tended (p = 0.06) to slightly 
decrease 5-HT1A mRNA levels (91.2 ± 3.8 %) after 48 h of treatment with 2.5 µM 13-cis-
RA (Fig. 3.3A).  10 µM 13-cis-RA treatment had no effect on 5-HT1A mRNA levels after 
48 h (93.9 ± 5.5% of control) and there were no differences in 5-HT1A mRNA levels due 
to either 2.5 or 10 µM 13-cis-RA treatment after 96 h (104.9 ± 5.6 and 104.9 ± 5.8% of 
vehicle control, respectively, Fig. 3.3A).   
To determine the effect of 13-cis-RA on 5-HT1A protein levels in RN46A-B14 
cells, semi-quantitative western blotting was performed.  Treatment of RN46A-B14 cells 
with 2.5 µM and 10 µM 13-cis-RA for 48 h significantly increased 5-HT1A levels to 
168.5 ± 20.0 and 148.7 ± 2.2% of control, respectively (Fig. 3.3B).  This increase was 
maintained after 96 h of 13-cis-RA treatment.  Thus, treatment of serotonergic cells with 
13-cis-RA increases 5-HT1A protein levels as early as 48 h after drug administration but 
does not affect 5-HT1A mRNA levels. 
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Effect of 13-Cis-RA Treatment on SERT mRNA and Protein Levels 
Northern blot analysis was also used to determine the effect of 13-cis-RA 
treatment on SERT mRNA levels. Treatment of RN46A-B14 cells with 2.5 or 10 µM 13-
cis-RA for 48 h did not affect SERT mRNA levels (Fig. 3.4A).  In contrast, 96 h of 
treatment with 10 µM 13-cis-RA tended (p = 0.10) to increase SERT mRNA levels to 
144.8 ± 20.7% of vehicle control.  In addition to the increase in mRNA levels, semi-
quantitative western blotting revealed that SERT protein levels were significantly 
increased after treatment with 2.5 µM and 10 µM 13-cis-RA for 48 h, reaching 142.5 ± 
11.1 and 119.2 ± 3.6% of vehicle control, respectively (Fig. 3.4B).  SERT protein levels 
tended to remain elevated after 96 h of treatment with 13-cis-RA (Fig. 3.4B). Therefore, 
treatment of serotonergic cells with 13-cis-RA leads to increased levels of SERT protein 
as early as 48 h after treatment and later to an increase in SERT mRNA. 
 
RAR and RXR expression 
RAR and RXR mediate gene transcription in response to retinoic acid.  Therefore, 
RT-PCR was used to examine RAR and RXR expression in RN46A-B14 cells and adult 
rat dorsal raphe tissue.  RARα, β, and γ as well as the RXRα, and β/γ isoforms were 
expressed in both RN46A-B14 cells and the raphe nuclei (Fig. 3.5), indicating that 
retinoid-mediated gene transcription via RAR/RXR/RARE can occur.  In RN46A-B14 
cells, the RARα expression level may be lower than RARβ and γ.  However, this RT-




We show here that prolonged treatment with 13-cis-RA increases intracellular 5-
HT and 5-HIAA levels, although the effect of 13-cis-RA on 5-HIAA levels was not 
significant.  Additionally, 13-cis-RA treatment increased 5-HT1A receptor and SERT 
protein levels, although it had little effect on their mRNA levels.  Previously, we showed 
that 13-cis-RA administration induced depression-related behavior in adolescent male 
mice (173). Disturbances in the serotonergic system are known to be involved in 
depression, including changes in expression of the 5-HT1A autoreceptor and SERT (166).  
An increase in expression of the 5-HT1A autoreceptor and SERT levels in the raphe nuclei 
following 13-cis-RA treatment may lead to decreased serotonergic availability at the 
synapse and thus contribute to the increase in depression-related behavior observed in 
vivo (173). 
We examined whether 13-cis-RA alters intracellular 5-HT levels or the levels of 
its metabolite, 5-HIAA and saw that 13-cis-RA increased 5-HT and tended to increase 5-
HIAA in vitro.  The increase in intracellular 5-HIAA parallels the increase in intracellular 
5-HT, thus we suspect the increase in intracellular 5-HIAA is due to the increase in 
intracellular 5-HT levels and occurred prior to chlorgyline treatment.  Ferguson et al. (39) 
examined the effects of 13-cis-RA treatment on monoaminergic systems in adult rats.  
While they found no effect on 5-HT or 5-HIAA content in brain tissue homogenates of 
either hippocampus or frontal cortex, 5-HIAA levels in the striatum were increased in 
male rats administered 13-cis-RA.  These data indicate that there are likely to be brain-
region specific effects of 13-cis-RA on 5-HT/5-HIAA levels.  Ferguson et al. (39) did not 
examine the raphe nuclei and thus it remains possible that 13-cis-RA may cause an 
increase in 5-HT and 5-HIAA in the raphe in vivo.  Although we did not examine release, 
recycling, or reuptake of 5-HT in this study, we speculate that increased levels of 
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intracellular 5-HT due to 13-cis-RA treatment could occur as a result of increased 
reuptake.  In these experiments we pre-treated the cells with fluoxetine prior to HPLC 
analysis, this SERT inhibitor was not added until we had preloaded the cells with 
tryptophan for 5-HT synthesis.  Therefore, greater 5-HT reuptake may be due to the 
ability of 13-cis-RA to increase SERT protein levels.  Alternatively, increased 
intracellular 5-HT levels could result from increased 5-HT synthesis due to the effects of 
13-cis-RA on the levels of synthetic enzymes such as tryptophan hydroxylase or amino 
acid decarboxylase.   
Although retinoids are known for their ability to alter gene transcription when 
binding to RAR/RXR heterodimers on RARE, other roles for retinoids are becoming 
evident.  ATRA has been shown to affect mRNA stability.  Although the mechanism is 
not completely understood, ATRA can reduce TNF-α mRNA stability in a RXR-
mediated manner in hepatocytes (14) increase keratin 19 mRNA stability in cultured 
keratinocytes (15) and increase protein stability in P19 cells (16).  Adult raphe and 
RN46A-B14 cells express RARα/β/γ and RXRα/β/γ (Fig. 4), indicating the presence of 
the cellular mechanisms for both retinoid receptor-mediated gene transcription.  We 
observed an increase in 5-HT1A protein after 48 and 96 h treatment with 13-cis-RA 
without an increase in mRNA.  It is possible that the increase in 5-HT1A protein level in 
response to 13-cis-RA treatment is due to increased translation of 5-HT1A mRNA or 
increased stability of the 5-HT1A protein.  We observed an increase in SERT mRNA after 
96 h of 13-cis-RA treatment.  This may reflect an increase in stability of the mRNA, but 
given the delay in increase of mRNA with treatment, it is possible that the SERT gene is 
not directly regulated by 13-cis-RA.  Instead, perhaps an intermediate gene, such as a 
transcription factor or a derepressor element, which regulates SERT expression, is 
transcriptionally activated by 13-cis-RA.  Because SERT protein but not mRNA levels 
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are changed after 48 h of treatment, 13-cis-RA treatment, in RN46A-B14 cells, may 
initially increase SERT protein stability or mRNA translation.  Increased transcription of 
early response genes that are transcription factors for SERT would then lead to the 
increase seen in SERT mRNA at 96 h and thus be the underlying cause of later elevated 
levels of SERT protein. 
Functionally, the 5-HT1A autoreceptor is involved in regulation of serotonergic 
neuron firing (153).  Activation of 5-HT1A autoreceptors residing on raphe nuclei by 5-
HT results in reduced firing of the raphe nuclei and therefore the amount of 5-HT in the 
synaptic cleft.  Both increased and decreased expression of the 5-HT1A receptor has been 
reported in depressed and suicidal patients (166).  In addition, polymorphisms in the 
human 5-HT1A promoter region have been linked to depression in some (163) but not all 
patients (184).  Interestingly, 5-HT1A null mice exhibit a decrease in immobility in both 
the forced swim test and the tail suspension test, consistent with an antidepressant-like 
effect in the tail suspension test (185).  In these knockout mice there is an increase in 
basal firing of serotonergic neurons (186) that is accompanied by enhanced extracellular 
5-HT release in vivo in hippocampus and frontal cortex (187), but not in striatum (188).   
Abnormalities in SERT expression may also contribute to depression (166). 
SERT removes 5-HT from synaptic cleft to regulate 5-HT signaling.  Two functional 
polymorphisms in the human SERT gene are associated with increased vulnerability to 
depression and that affect the response to antidepressants (189). These polymorphisms of 
the SERT gene are associated with reduced SERT expression, reduced 5-HT reuptake 
rate (164, 190, 191) and increased susceptibility to depression (164, 165, 192).  Also, 
SERT null mice exhibit decreased immobility in the tail suspension test (170) and siRNA 
knockdown of SERT in adult mice reduced time spent immobile in the forced swim test 
(193).  Interestingly, SERT knockout mice exhibit a gene dose-dependent decrease in 
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SERT protein levels, 5-HT uptake and an increase in extracellular 5-HT levels (194-196).  
Since the function of SERT is to remove 5-HT from the synaptic cleft, both increases and 
decreases in SERT may disrupt 5-HT signaling, affecting downstream neuronal targets, 
which may eventually result in depression.   
Given that the roles of the presynaptic 5-HT1A receptor and SERT are to regulate 
5-HT signaling, increases of the 5-HT1A presynaptic-receptor and SERT due to 13-cis-RA 
treatment may inhibit firing and reduce 5-HT signaling from the raphe to other brain 
regions.  Such impairment in serotonergic neurotransmission could contribute to the 13-
cis-RA-induced increase in depression-related behaviors observed in mice.  
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Figure 3.1:  Regulation of 5-HT in a raphe neuron and antidepressant activity. 
5-HT content within a raphe neuron is controlled by synthesis, packaging into vesicles for 
release, reuptake by SERT, and breakdown by MAO.  The 5-HT1A receptor is one 
receptor that regulates 5-HT release.  Activation of the 5-HT1A receptor by 5-HT prevents 
5-HT release by preventing depolarization and thus raphe neuron firing.  Antidepressants 
that target the serotonergic system work to increase the amount of 5-HT in the synaptic 
cleft.  Reserpine, which is a depressant, prevents packaging of 5-HT into vesicles for 




Figure 3.2:  Effect of 13-cis-RA treatment on intracellular 5-HT and 5-HIAA levels in 
cultured serotonergic cells. 
Representative HPLC tracing for cell lysate (A) and 1 pmol standard (B).  5-HT and 5-
HIAA retention times are indicated.  Intracellular 5-HT and 5-HIAA content (C and D).  
Cells were differentiated for 8 d before treatment with 0, 2.5, or 10 µM 13-cis-RA for 48 
or 96 h.  Prior to harvesting, cells were incubated with 10 µM tryptophan and 10 µM 
chlorgyline for 30 min, then 10 µM fluoxetine was added for another 30 min.  Cells were 
lysed and 5-HT and 5-HIAA content were detected electrochemically via  HPLC .  
Results shown 5-HT (C) and 5-HIAA (D) are mean ± SEM for four separate 
experiments.  Statistical analysis was performed using t-tests comparing each 13-cis-RA 
concentration to control. 
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Figure 3.3:  Effect of 13-cis-RA on 5-HT1A mRNA and 5-HT1A protein levels. 
Cells were differentiated for 8 d and then cultured with 0, 2.5, or 10 µM 13-cis-RA for 48 
or 96 h.  (A) Total RNA was harvested and subjected to northern blot analysis for 5-HT1A 
and GAPDH mRNA (1269 and 1307 bp respectively) as described in Materials and 
Methods.  GAPDH was used to correct for loading differences.  Northern blot analysis 
was repeated four separate times with similar results; a representative northern blot is 
shown.  (B) Total protein was harvested and subjected to western blot analysis for 5-HT1A 
and β-actin (30 and 42 kDa respectively) as described in Materials and Methods.  β-actin 
was used to correct for loading differences. Western blot analysis was performed three 
separate times with similar results; a representative western is shown.  Values reported 
are mean ± SEM.  Statistical analysis was performed using t-tests comparing each 13-cis-
RA concentration to control.  *P < 0.05, **P < 0.01; significantly different from control. 
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Figure 3.4:  Effect of 13-cis-RA treatment on SERT mRNA and protein levels. 
Cells were differentiated for 8 d and then cultured with 0, 2.5, or 10 µM 13-cis-RA for 48 
or 96 h.  (A) Total RNA was harvested for northern blot analysis of SERT and GAPDH 
mRNA (3190 and 1307 bp respectively) as described in Materials and Methods.  GAPDH 
was used to demonstrate equal loading.  (B) Total protein was harvested and subjected to 
western blot analysis for SERT and β-actin (75 and 42 kDa respectively) as described in 
Materials and Methods.  β-actin was used to demonstrate equal loading.  These 
experiments were performed three separate times with similar results; representative 
western and northern blots are shown.  Results are mean ± SEM for three separate 
experiments.  Statistical analysis was done using t-tests comparing each 13-cis-RA 
concentration to control.  *P < 0.05, **P < 0.01; significantly different from control. 
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Figure 3.5:  Expression of RAR and RXR in RN46A-B14 cells and rat raphe tissue. 
(A) RN46A-B14 cells were differentiated for eight days and total RNA was reverse 
transcribed.  cDNA was then amplified with primers specific for RAR and RXR.  (B) 
Total RNA from rat raphe tissue was reverse-transcribed in a one-step RT-PCR with the 
same primers for RAR and RXR. All isoforms of RAR and RXR were expressed in 
RN46A-B14 cells and rat raphe tissue.  The RARα, RARβ, RARγ, PCR amplicons were 
54, 178, and 175 bp in length.  The RXRα and RXRβ/γ amplicons were 172 and 102 bp 
in length. 
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Chapter 4:  Chronic 13-Cis-RA Administration Disrupts Functional 
Connections between the Serotonergic and Hippocampal Systems in 
Adolescent Male Mice 
ABSTRACT 
We previously showed that chronic administration of 13-cis-RA induces 
depression-related behaviors in adolescent male mice and that 13-cis-RA can alter 
components of the serotonergic system in vitro.  Other work has shown that hippocampal 
neurogenesis is reduced by chronic 13-cis-RA treatment in young-adult male mice.  
Furthermore, orbitofrontal cortex metabolism is decreased due to 13-cis-RA treatment in 
humans.  In the current study, cytochrome oxidase (CO) activity, a metabolic marker that 
reflects steady state neuronal firing, was measured in various regions of the brain to 
determine the effects of 13-cis-RA on neuronal activity.  Adolescent male mice were 
administered vehicle or 1 mg/kg/day 13-cis-RA, i.p., for 6 weeks, tested for depression-
related behaviors, and then CO activity was analyzed.  We show that chronic 13-cis-RA 
administration tended to decrease CO activity in the median raphe nuclei and 
significantly decreased the CO activity in the inferior rostral linear nucleus of the raphe.  
Although there was no change in CO activity in the dorsal raphe nuclei or the 
hippocampal regions in 13-cis-RA treated animals, these regions become functionally 
uncoupled by 13-cis-RA treatment.  Furthermore, a path analysis of the connectivity 
between the hippocampus to the lateral habenula through the dorsal raphe nuclei showed 
that this circuit is disrupted in 13-cis-RA treated animals.  Interestingly, total immobility 
in the tail suspension and forced swim tests inversely correlated to the CO activity in the 
dentate gyrus in 13-cis-RA treated mice, but not control treated mice.   Taken together 
these data show that 13-cis-RA is capable of altering brain metabolism and disrupting 
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functional connectivity between the serotonergic system and the hippocampus possibly 
leading to the previously observed increase in depression-related behaviors. 
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INTRODUCTION 
We previously showed that chronic 13-cis-RA administration to adolescent male 
mice induced depression-related behaviors as measured by total immobility in the last 
four minutes of the tail suspension and forced swim tests.  We also showed that 13-cis-
RA treatment of serotonergic cells in vitro increased protein levels of the 5-HT1A receptor 
and SERT (197), two components of the serotonergic system that regulate neuronal 
firing.  Increases in the 5-HT1A receptor and SERT proteins in vivo could lead to 
decreased serotonergic signaling.  13-Cis-RA administration has also been shown to 
decrease hippocampal neurogenesis in mice (97) and decrease metabolism in the 
orbitofrontal cortex of human patients taking Accutane (94).  
Metabolic differences in the brain due to depression have been shown using 
human neuroimaging studies as well as animal models.  Human studies have shown 
abnormalities in blood flow and metabolism of the frontal cortex regions of depressed 
patients.  For instance, depressed patients have a pattern of decreased orbitofrontal 
cortical metabolism (198) and anterior cingulate cortex metabolism (199) and increased 
infralimbic cortical metabolism (199).  
Several animal models of depression have also begun to elucidate metabolic 
differences in the brain.  For instance, alpha-methyl-para-tyrosine (a catecholamine 
synthesis inhibitor) administration, chronic stress, and short term withdrawal from 
amphetamine all produce decreased 14C-2-deoxyglucose uptake in the prefrontal motor 
cortex and increased 14C-2-deoxyglucose uptake in the lateral habenula (200).  The 
congenitally learned helpless rat is an inbred strain that exhibits increased vulnerability to 
learned helplessness and has also proven to be a useful model for human depression.  The 
congenitally learned helpless rat has altered cortex metabolism that mimics the 
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metabolism abnormalities seen in the frontal and cingulate regions of depressed humans.  
Further characterization of metabolic differences in the congenitally learned helpless rat 
compared to normal rats has revealed differences in CO activity throughout the brain 
[reviewed in (137)].  In the congenitally helpless rats, regions that were hypometabolic 
compared to controls include the orbitofrontal cortex, the lateral septal nucleus, the raphe 
nuclei, and the ventral tegmental area [reviewed in (137)].  Brain regions that were 
hypermetabolic in the congenitally helpless rats when compared to controls include the 
subgenual cingulate cortex, the infralimbic cortex, the hippocampus, the habenula, the 
paraventricular hypothalamus, the interpeduncular nucleus, and the subiculum [Reviewed 
in (137)]. 
Cytochrome oxidase (CO) is the terminal enzyme in the electron transport chain 
that catalyzes the transfer of electrons from ferrocytochrome C to oxygen to form water 
and, ultimately, ATP (201).  Other commonly used measures of brain metabolic activity, 
such as positron emission tomography (PET) or functional magnetic resonance imaging 
(fMRI), measure glucose uptake and/or blood flow to specific regions of the brain, and 
PET imaging is similar to the autoradiographic 14C-2-deoxyglucose uptake used to 
measure glucose uptake in animals.  However, while glucose uptake and blood flow 
represent state dependent neuronal activity spanning approximately 45 minutes, CO 
activity reflects cumulative long term neuronal activity (201).   
Because the serotonergic, hippocampal, and frontal cortical systems are involved 
in depression, alterations in metabolism in the serotonergic and hippocampal regions due 
to 13-cis-RA treatment may elucidate the underlying mechanism by which 13-cis-RA 
induces depression-related behaviors.  Therefore, the objective of this study was to 
determine the effect of chronic 13-cis-RA treatment on brain metabolism in the same 
adolescent animals that were treated with 13-cis-RA or vehicle and then tested for 
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depression-related behaviors.  We used CO activity to measure metabolic activity and 
therefore long term neuronal activity in the brain.  Our goal was to determine if 13-cis-
RA induces long-term brain metabolic changes consistent with those seen in depressed 




The animals used for the metabolic mapping were the same as those used in 
Chapter 2 of this dissertation.  Briefly, young, adult male DBA/2J (Jackson Laboratories, 
Bar Harbor, ME) mice were three weeks old at arrival and four weeks old at the start of 
treatment.  Mice were group-housed four per cage and maintained under a 12:12 h 
light/dark cycle.  Food and water were provided ad libitum.  All procedures and tests 
performed on animals were approved by the University of Texas IACUC, protocol 
number 04100403, according to the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals. 
 
Treatment 
Animals were allowed to adapt to the University of Texas animal facility for one 
week prior to initial injection.  Animals were handled during the first week to reduce the 
stress of receiving daily injections.  A 2 mg/mL stock solution of 13-cis-RA in dimethyl 
sulfoxide (DMSO) was stored for up to one week at -20 ºC.  The stability of 13-cis-RA 
after one week of storage was confirmed by comparing the absorbance at 354 nm to that 
of a freshly prepared sample (97).  Sterile injection samples were prepared in the dark.  
Injections were performed one hour prior to the start of the dark cycle in the same room 
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where the animals were housed and the same person performed all injections.  Treated 
animals (n = 12) received daily i.p. injections of 1 mg/kg/day 13-cis-RA (Sigma, St. 
Louis, MO) dissolved in sterile 50% DMSO/50% saline (0.9%) to a final volume of 200 
µL.  Control animals (n = 12) were administered 200 µL of vehicle (50% DMSO/50% 
saline), i.p., daily.  Animals were injected for 6 weeks prior to behavioral testing.  Daily 
injections continued throughout the testing period and all animals received injections 14 h 
before any behavioral testing to eliminate any acute effects of injection. Only one 
behavioral test was performed each day.  The behavioral experiments were conducted in 
the following order:  tail suspension test, forced swim test, open field test, and rotarod 
test. Approximately 24 h elapsed between each of the tests. 
 
Tissue Processing 
After cervical dislocation, animals were decapitated and the brains were removed 
intact, frozen rapidly in isopentane, and stored at -40˚C until they were sectioned at -20˚C 
using a cryostat (Leica, Bannockburn, IL) into 40 µm sections and thaw mounted onto 
slides.  The slides were then kept frozen at -40˚C until they were processed using 
quantitative CO histochemistry.   
CO histochemical staining was performed as described in (202), the slides were 
first incubated in 0.1 M phosphate buffer (with 10% w/v sucrose and 0.5% 
gluteraldehyde, pH 7.6) for five min.  The tissues were then transferred to a series of four 
exposures to 0.1 M phosphate buffer (containing 10% w/v sucrose) for five min each.   
The tissues then underwent metal intensification (0.05 M Tris buffer, pH 7.6, with 275 
mg/L cobalt chloride, 10% w/v sucrose, 0.5% dimethylsulfoxide) for 10 min.  These 
buffers were stored at 4˚C and poured prior to the first incubation so that the tissues could 
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gradually warm to room temperature.  Following the metal intensification incubation, the 
tissues were placed in a room temperature phosphate buffer rinse. 
The CO staining was done with a 60 min incubation in 0.1 M phosphate buffer 
containing 350 mg diaminobenzidine tetrahydrochloride, 52.5 mg cytochrome c, 35 g 
sucrose, 14 mg catalase, and 1.75 mL DMSO in 700 mL total volume, at 37˚C.  The 
reaction was stopped by fixing the tissue in 0.1 M phosphate buffer containing 4% 
formalin and 10% w/v sucrose.  Finally, the tissues were dehydrated in a series of ethanol 
baths (30%, 50%, 70%, 95%, 95%, 100%, 100%, five min each) and then cleared with 
xylene and coverslipped with permount.    
 
Preparation of CO Standards and Densitometric Analysis 
In order to quantify enzyme activity and to control for staining variability across 
batches of CO staining, sets of tissue homogenate standards were included in each batch 
of slides.  The tissue homogenate was prepared as described previously (202) and the 
enzymatic activity of CO activity was assayed as described in (203).  Activity units were 
defined at pH 7 and 37˚C, where one unit oxidizes one µmol of reduced cytochrome 
c/min (µmol/min/g tissue wet weight).  The remaining tissue homogenate was frozen and 
stored at -40˚C.   
Prior to the CO staining procedure, the standard homogenate was sectioned into 
10, 20, 40, 60, and 80 µm sections, and thaw mounted onto slides, with two replicates of 
each thickness per slide.  Two slides of standards were incubated with each batch during 
the CO staining procedure.  The activity values determined by the spectophotometric 
method were correlated with the corresponding optical density (OD) measurements of 
each standard, taken with an image-processing system as described in (203).  The 
resulting linear regression equations (r2 > 0.95) were used to convert OD readings from 
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chosen brain regions into CO activity values.  The activity values were then used in the 
statistical analysis of this study. 
The image processing system (JAVA, Jandel Scientific, Corte Madera, CO) was 
used to record OD readings from 15 brain regions as described in the next section.  
Microscope slides of the stained tissue were placed on a DC-powered light box and the 
image captured with a black and white video camera (Javelin JE2362).  The signal was 
then transmitted to a Targa M-8 frame grabber mounted in an Everex 486 computer 
where the image was digitized.  To correct for background and optical distortions within 
the camera, a coverslipped glass slide and a calibrated optical density tablet (Kodak, 
Rochester, NY) were used to calibrate the system.  The sampling window (square-
shaped) was adjusted for each region so that it would be as large as possible to take two 
to three readings over the region of interest in one hemisphere per slice per subject and 
three brain slices per subject were examined.  These readings were then averaged to 
represent CO activity for each region for an individual animal.  Prior to performing the 
image analysis, the slides were coded so that the person performing the image analysis 
was blinded to the treatment group. 
Morphometric Analysis 
Morphometric analysis of the hippocampus was performed on the cytochrome 
oxidase stained slides as described previously in (204).  Briefly, images of the brain slices 
were captured as in the densitometric analysis above and the Jandel software’s algorithm 
calculated areas of the right and left hemi-brain section as well as the right and left hemi-
hippocampus.  The first section measured was the first appearance of the hippocampus at 
the bregma level -0.94, as determined with a mouse brain atlas (205), and every third 
section was measured until bregma level -4.04.  The hemi-hippocampal area was 
normalized to the hemi-brain section area (hemi-hippocampal area/hemi-brain section 
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area x100) for each bregma level.  The bregma levels were collapsed mathematecally to 
seven bregma levels and each bregma level consited of the following levels: -1 (-0.94 to -
1.06), -1.5 (-1.22 to -1.58), -2 (-1.70 to -2.08), -2.5 (-2.18 to -2..54), -3 (-2.70 to -3.08), -
3.5 (-3.16 to -3.52), and -4 (-3.64 to -4.04) mm from bregma.  The % hippocampal area 
for each bregma level was determined by averaging the % hemi-hippocampal area for the 
bregma levels within the main bregma level for both the right and left sides of the brain.   
Hippocampal volumes were estimated by the Cavalieri principle (206) using a 
grid printed on acetate overlay.  Each square on the grid corresponded to an area of 0.56 
mm2.  The grid was placed over the image on the computer screen and each grid crossing 
was counted for each hemi-section of the hippocampus.  The area of the grid was 
corrected for the magnification (area/magnification2).  To calculate the hippocampal 
volume, the number of grid crossings was multiplied by 180.65 µm, which was the 
corrected grid area, and then by 120 µm, which was the tissue thickness of the three 
sections until the next section that was analyzed.  The total hippocampal volume was the 
sum of the hippocampal volumes across all sections for the left and right sides.   
Selection of Regions for Imaging 
Because our animals exhibited depression-related behaviors (173), we chose to 
examine the areas of the brain that have metabolic differences in the above mentioned 
models of induced depression, learned helplessness, and areas known to be affected by 
13-cis-RA.  Specifically, we chose to look at the following regions:  orbitofrontal cortex, 
raphe nuclei, hippocampus, cingulate cortex 2, infralimbic cortex, lateral septal nucleus, 
habenula, paraventricular hypothalamus, ventral tegmental area, interpeduncular nucleus, 





Regional Mean CO Activity 
The average CO activity for each region of interest was calculated on a group 
basis.  Two-tailed, Student’s t-tests were performed to test for differences between 
vehicle control and 13-cis-RA treated animals in Excel (XP 2002; Microsoft).  Tissue 
quality was poor in some regions of interest and thus the number of animals (n) for the 
regions varied.  Data are expressed as mean ± SEM µmol/min/g wet tissue weight.  
 
Interregional Correlations 
SPSS was used to determine the Pearson product moment correlations and 
whether or not these correlations were significantly different from zero using a two-tailed 
Student’s t-test.  A modified jackknife approach was performed to verify that the 
significant correlations were not driven by a single animal.  In this modified jackknife 
approach, one animal at a time is removed from the correlation and the correlation is 
recomputed with n-1 data points.  That animal is then placed back in the group and the 
next animal is removed and the correlation recalculated with the new n-1 data points. 
This process is repeated until each animal has been removed and the respective 
correlation is calculated.  The highest p-value is then reported and the correlations are 
evaluated from the jackknife approach.  If the p-value for the original correlation was less 
than 0.05 and the p-value for the correlation after the modified jackknife remained less 
than 0.1 the correlation was considered significant and the original correlation and p-
value were reported.  Positive correlations indicate that the CO activity of both regions 
move in the same direction, i.e. lower CO activity in region A predicts lower CO activity 
in region B and vice versa.  Negative correlations indicate the CO activities of the regions 
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move in opposite directions, i.e. lower CO activity in region A predicts higher CO 
activity in region B.   
To determine if the correlations from the 13-cis-RA treated group were different 
from the correlations of the control treated group, the correlations for each group were 
first converted to a z score.  The between group z scores were then determined to be 
different from each other using the Fischer’s z test.  Correlations for the 13-cis-RA 
treated group were considered to be different from the control correlations if the p-value 
reported for the Fisher’s z-test was less than 0.05. 
 
Path Analysis 
Path analysis, also called structural equation modeling, was performed similar to 
that described in (207).  Briefly, a path was first identified using known anatomical 
connectivity based on previous literature.  The path we chose to analyze is presented in 
Fig. 4.2.  In path analysis, causal relationships between regions are represented by path 
coefficients for connecting regions, denoted by the arrow.  The path coefficients represent 
a numeric weight, or influence, of one brain region on a connected brain region.  The 
path coefficients are determined in an iterative process whereby a theoretical model is 
data-fitted to the interregional correlation data that resulted from the experimental CO 
values.  In this particular model, the path coefficient from the lateral habenula to the 
dorsal raphe nuclei represents the proportion of CO activity in the dorsal raphe nuclei that 
is predicted by the CO activity of the lateral habenula.  Likewise, the path coefficient 
between the dorsal raphe nuclei and the hippocampus represents the proportion of CO 
activity of the hippocampus determined by the CO activity of the dorsal raphe nuclei.  
The path coefficients were determined for each of the control and 13-cis-RA treated 
groups using LISREL (version 8.54, Scientific Software).  LISREL first estimates the 
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unknown parameters of path coefficients and residuals using a least-squares estimation.  
The residuals reflect external influence from regions not included in the model, as well as 
the influence of a region upon itself.  For instance, because the lateral habenula does not 
have inputs that would influence the CO activity in our model, the residual is 1.0, 
indicating that all of the CO activity in the lateral habenula is influenced by an outside 
source or by itself.  Iterations of calculated path coefficients and residuals are then used 
to determine the optimal parameters that minimize the deviation of the theoretical 
covariances from the experimental covariances.   
A stacked model approach was used to compare the theoretical model generated 
for the control group versus the theoretical model generated for the 13-cis-RA treated 
group.  To perform this approach, two more models are determined, a null model and an 
alternative model.  The null model is generated by forcing the path coefficients for the 
control group and the 13-cis-RA treated group to be equal.  The alternative model is the 
model derived if the coefficients for each group are allowed to vary. A χ2 goodness-of-fit 
statistic is computed for the ability of each model to fit the original correlation matrix and 
then summed for each group.  The degrees of freedom (df) for each group were also 
summed.  The summed χ2 for the alternative model was then subtracted from the χ2 of the 
null model and the degrees of freedom of the alternative model subtracted from the 
degrees of freedom of the null model.  The χ2diff(dfdiff) was then used to determine the 
probability that the two models are different from each other, expressed as a p-value, 
based on the null hypothesis that the path coefficients of the control group model and the 




The immobility of the last four min of both the tail suspension and forced swim 
tests were summed and called “Total Immobility”. SPSS was used to determine the 
Pearson product moment correlation between the Total Immobility and each region of 
interest and whether or not these correlations were significantly different from zero using 
a two-tailed Student’s t-test.  Again, the correlations were subjected to the modified 
jackknife approach to verify the correlations were not driven by a single animal.  The 
same criteria as before were used to determine significant correlations, i.e. the original 
correlation p-value was less than 0.05 and the modified jackknife p-value was less than 
0.01.  Positive brain-behavior correlations indicate that the Total Immobility is increased 
with the CO activity the region of interest, i.e. higher CO activity in region A predicts 
more Total Immobility and vice versa.  Negative correlations indicate the Total 
Immobility and CO activity in the region of interest move in opposite directions, i.e. 
lower CO activity in region A predicts more Total Immobility.  Correlations were 
considered significant if p < 0.05. 
 
Morphometric Analysis 
Group comparisons of % hippocampal areas at the various bregma levels were 
evaluated using a repeated measures ANOVA in SPSS.  Comparison of total 
hippocampal volumes between groups were made using a Student’s t-test in Excel.  
Differences were considered significant at p < 0.05.   
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RESULTS 
13-Cis-RA Tends to Decrease CO Activity in the Median Raphe Nuclei 
CO activity was measured to assess the effect of 13-cis-RA on brain metabolism 
in regions thought to be involved in depression (Table 4.1).  Although Bremner et al. 
found decreased metabolism in the orbitofrontal cortex due to 13-cis-RA administration 
in humans (94), 13-cis-RA treatment had no effect on CO activity in the orbitofrontal 
cortex in this study.  However, consistent with the ability of 13-cis-RA to alter 
serotonergic components in vitro (197), 13-cis-RA treatment tended to decrease CO 
activity in the median raphe nuclei.  The CO activity of the control group was 294.1 ± 9.8 
µmol/min/g wet tissue weight, while the CO activity of the 13-cis-RA treated group was 
267.7 ± 11.3 µmol/min/g wet tissue weight (p = 0.09).   We also found a significant 
decrease in CO activity in the inferior rostral linear nucleus of the raphe (p = 0.03) a 
region that was previously thought to be a part of the serotonergic system and that 
receives input from the dorsal raphe nuclei (208).  However, other work indicates that 
this region may also be associated with the ventral tegmental area (209-211).  The 
somatosensory 1 barrel field region receives input from the whiskers and is not known to 
be involved in depression-related behaviors, thus CO activity in this region was used as a 
negative control.  There was no difference in CO activity in the somatosensory 1 barrel 
field region as expected.  Furthermore, whole brain activity was not different between 
groups.  These data show that chronic 13-cis-RA administration is capable of disrupting 
serotonergic activity, not only at the serotonergic cell bodies, but also at sites of efferent 
serotonergic projections such as the rostral linear nucleus of the raphe. 
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13-Cis-RA Reverses the Correlations between the CO Activity of Hippocampal 
Regions and CO Activity of the Dorsal Raphe Nuclei 
The dorsal and median raphe nuclei contain the main 5-HT producing cells in the 
brain thought to be involved with mood and cognition (52, 53).   There were no 
significant metabolic differences in the dorsal raphe nuclei between the 13-cis-RA treated 
and control groups.  However, because the serotonergic system is thought to be involved 
in depression, and because 13-cis-RA has been shown to decrease hippocampal 
neurogenesis, we wanted to determine the effects of 13-cis-RA on interregional CO 
activity correlations between the dorsal or median raphe nuclei and the hippocampus.  In 
control animals, the CO activity of the dorsal raphe nuclei is significantly correlated to 
the CO activity of the CA1 (r = 0.83, p = 0.003) and the CA3 regions of the hippocampus 
(r = 0.82, p = 0.004) as well as to the dentate gyrus (r = 0.70, p = 0.02) (Fig. 4.3A-C).  
Interestingly, in 13-cis-RA treated animals, these correlations are lost.  Specifically, the 
correlations between the CO activity of the dorsal raphe nuclei and the CO activities of 
the CA1 and CA3 hippocampal regions and the dentate gyrus in 13-cis-RA treated 
animals were r = -0.14 (p = 0.71), r = -0.07 (p = 0.84), and r = 0.02 (p = 0.96), 
respectively (Fig. 4.3A-C).  Furthermore, the correlations between the dorsal raphe nuclei 
and the CA1 and CA3 regions in control animals are significantly different from the 
correlations in 13-cis-RA treated animals (p = 0.01 and p = 0.02, respectively).  However, 
correlations between the dorsal raphe nuclei and the dentate gyrus were not significantly 
different between control and 13-cis-RA treated mice (p = 0.11) (Fig. 4.3D).  These data 
show that chronic 13-cis-RA treatment uncouples the dorsal raphe nuclei from the 
hippocampus, revealing that 13-cis-RA is targeting multiple brain systems thought to be 
involved in depression. 
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13-Cis-RA Significantly Disrupts the Communication Path between the Lateral 
Habenula and the Hippocampus 
Although there is little known about the relationship between the lateral habenula 
and the hippocampus, Ferraro et al. (212) showed that the lateral habenula can affect the 
hippocampus by regulating the dorsal raphe nuclei.  Specifically, the lateral habenula has 
an excitatory effect on the CA1 region of the hippocampus by exerting an inhibitory 
effect on the dorsal raphe nuclei (212).  The dorsal raphe nuclei also sends projections to 
the CA3 region of the hippocampus as well (208).  Because the dorsal raphe nuclei 
became uncoupled from the regions of the hippocampus, we wanted to determine the 
effects of 13-cis-RA treatment on the following network:  lateral habenula → dorsal 
raphe nuclei → hippocampus, and we included the known anatomical connections of the 
intrinsic pathway of the hippocampus:  dentate gyrus → CA3 → CA1  (Fig. 4.2).  We 
conducted a path analysis to determine if these paths were different in control versus 13-
cis-RA treated animals.  Bivariate correlations for the lateral habenula, dorsal raphe 
nuclei, and hippocampus were used to calculate the path coefficients for the control (Fig. 
4.4A) and 13-cis-RA (Fig. 4.4B) treated groups.  The χ2 analysis revealed that the 
alternate model, where the correlations were allowed to vary, was significantly different 
from the null model with fixed paths (χ2diff(8) = 17.03, p = 0.03).  This indicates that the 
interactions between the lateral habenula and the dorsal raphe nuclei and the 
hippocampus are significantly different between the control and 13-cis-RA treated 
groups.  Additionally, the intrinsic pathway of the hippocampus is significantly changed 
by 13-cis-RA treatment.  In the control group, the lateral habenula has a positive 
influence on the dorsal raphe nuclei whereas the influence of the lateral habenula on the 
dorsal raphe nuclei in 13-cis-RA treated animals is negative.  Furthermore, the residual 
influence on the dorsal raphe nuclei is increased after 13-cis-RA treatment.  
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The dorsal raphe nuclei has a positive influence on both the CA1 and CA3 region 
of the hippocampus in control animals.   This influence is reduced and is negative after 
13-cis-RA treatment, indicating that these two regions, the dorsal raphe nuclei and the 
hippocampus, are operating independently of one another.  The influences of the dentate 
gyrus on the CA3 region and the CA3 region on the CA1 region are increased by 13-cis-
RA treatment.  These data show that chronic 13-cis-RA treatment is capable of altering 
functional paths, not just correlations, in the mature brain. 
 
Total Immobility is Correlated to CO Activity in the Dentate Gyrus 
Because the brains were extracted from the same animals that were subjected to 
behavioral testing, we wanted to know if the behaviors correlated to CO activity in any 
region that we measured.  Additionally, since we evaluated the activity in the tail 
suspension and forced swim tests together as one measure of depression (173), we 
decided to compare total immobility to the CO activities of the various regions.  The 
Total Immobility did not correlate to any region in the control group.  Interestingly, in the 
13-cis-RA treated group, the Total Immobility significantly and inversely correlated to 
the CO activity in the dentate gyrus (r = -0.94, p < 0.001) (Fig. 4.5A-B).  The fact that the 
decreased CO activity in the dentate gyrus strongly predicts Total Immobility in the 13-
cis-RA treated group, but not the control group, indicates that the more 13-cis-RA 
decreased dentate gyrus activity, the more it increased depression-related immobility. 
 
13-Cis-RA Has No Effect on Hippocampal Volume or Morphology 
The results discussed above have indicated that 13-cis-RA is targeting the 
hippocampus.  Because 13-cis-RA effects neurogenesis in the hippocampus (97) and 
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because hippocampal volumes are thought to be reduced in depressed patients (63-65) the 
volumes of the hippocampus were determined and the % hippocampal area at various 
bregma levels were calculated and compared between groups.  13-Cis-RA had no effect 
on hippocampal volume.  The hippocampal volume was 29006128 ± 1086737 µm3 in 
control animals (n = 10) and 29697935 ± 786124 µm3 in 13-cis-RA treated animals (n = 
12).  There was also no effect on % hippocampal area at any bregma level (Figure 4.6). 
 
DISCUSSION 
CO activity in the brain represents long-term neuronal activity and interregional 
correlations of CO activity indicate functional connectivity between these regions.  
Decreased CO activity due to 13-cis-RA treatment therefore represents decreased 
neuronal firing in the region of interest.  Furthermore, differences in interregional 
correlations between control and 13-cis-RA treated mice represent alterations in 
communication within the brain regions due to 13-cis-RA treatment.  We show here that 
chronic treatment of adolescent male mice for 6 weeks with 1 mg/kg/day of 13-cis-RA 
tends to decrease CO activity in the median raphe nuclei and significantly decreases the 
CO activity in the rostral linear nucleus of the raphe when compared to animals 
administered an equal volume of vehicle.  Additionally, in control animals, the CO 
activity in the dorsal raphe nuclei significantly correlates to the CO activity in the CA1 
region, CA3 region, and dentate gyrus of the hippocampus.  These correlations are lost in 
the 13-cis-RA treated animals.  Furthermore, a path analysis evaluating the connectivity 
of the lateral habenula to the hippocampus via the dorsal raphe nuclei revealed that this 
path is also disrupted by 13-cis-RA as seen by a disconnect of the dorsal raphe nuclei 
from each of the hippocampal regions and from the lateral habenula.  Additionally, the 
path analysis revealed that the regional influences of the dentate gyrus on the CA3 region 
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and the influence of the CA3 region on the CA1 region is increased by 13-cis-RA 
treatment.  Moreover, the Total Immobility in the tail suspension and forced swim tests 
correlated inversely to the CO activity in the dentate gyrus of 13-cis-RA treated, but not 
control, animals.  Although 13-cis-RA seems to be disrupting communication to the 
hippocampus, there was no effect on volume or % hippocampal area due to 13-cis-RA 
treatment.  A summary of the CO activity changes, as well as the correlation changes can 
be seen in Fig. 4.7.  The behavior-region and region-region correlations, as well as the 
differences between the group correlations are summarized in Table 4.2.  Combined, 
these data show that 13-cis-RA treatment alters serotonergic and hippocampal function, 
which could be responsible for the depression-related behaviors we observed previously.   
Only one previous study examined the effects of 13-cis-RA on brain metabolism.  
Bremner et al. (94) found that four months of 13-cis-RA treatment decreased 
orbitofrontal cortex metabolism when compared to baseline metabolism in each 
individual.  In contrast, there was no change in orbitofrontal cortex metabolism in 
antibiotic treated control patients over the four month period (94).  None of the 13-cis-
RA treated patients were depressed, according to the Hamilton depression rating scale.  
However, patients exhibiting decreased orbitofrontal cortex metabolism reported mood 
changes as observed by themselves, their family, or the staff conducting the study (94).  
Although we found increased depression-related behaviors in the adolescent male mice 
that received chronic 13-cis-RA treatment (173), we did not find altered metabolism in 
the orbitofrontal cortex of 13-cis-RA treated animals.  This may be due to differences in 
homology between these brain regions in humans and mice, or it may be due to 
differences in technique.  The PET scans measure glucose uptake, which is representative 
of neuronal response to environmental conditions that span over about 45 min (203).  In 
contrast, the CO activity denotes steady state activity of a given brain region (201, 203).  
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Therefore, although steady state orbitofrontal cortex neuronal demands may not be 
different due to 13-cis-RA treatment, orbitofrontal cortex response to environmental cues 
may be suppressed due to 13-cis-RA treatment. 
We expected chronic 13-cis-RA administration to alter CO activity according to 
the available models of depression.  We were surprised to see very few differences in the 
regional group average CO activities of the 13-cis-RA treated mice when compared to 
control mice because there was a significant difference in depression-related behaviors, 
specifically increased immobility, in the 13-cis-RA treated mice when compared to 
control mice (173).  However, we did find that the CO activity in the median raphe 
nuclei, one of the main 5-HT producing systems in the brain, of 13-cis-RA treated mice 
tended to be lower than that of the control mice.   
The ability of 13-cis-RA to reduce CO activity in the inferior rostral linear nuclei 
may, in part, account for the depression related behaviors induced by 13-cis-RA.  The 
dorsal raphe nuclei projects to the rostral linear nucleus of the raphe (208).  Additionally, 
the rostral linear nucleus of the raphe has been found to have efferent projects directly to 
the lateral habenula, the dorsal raphe nuclei and to the ventral tegmental area, a largely 
dopaminergic area involved in reward (209).  Historically, this region has been 
considered to be a part of the raphe nucleus, and brain atlases continue to call it the 
rostral linear nucleus of the raphe.  Furthermore, although a mouse atlas was used to 
identify brain regions within the slices analyzed, the Paxinos rat atlas states that regions 
called the raphe were identified consistently with serotonergic labeling (213).  From the 
stereological study performed in Chapter 5, we found that serotonergic labeling of the 
raphe nuclei cell bodies did not occur until approximately bregma level -4.04, where the 
median raphe nuclei begins (Fig. 5.1A).  Additionally, the rostral linear nucleus of the 
raphe has been suggested to be a GABAergic containing component of the ventral 
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tegmental area (209).  The ventral tegmental area is involved in reward, and depressive 
symptoms such as anhedonia implicate that this regions is disrupted in depression.  The 
ventral tegmental area has decreased CO activity in congenitally learned-helpless rats 
(74).  However, raphe nuclei and the ventral tegmental area did not exhibit covaried CO 
activity with the inferior rostral linear nucleus of the raphe.   Whether the rostral linear 
nucleus of the raphe is a component of the serotonergic raphe nuclei or the dopaminergic 
ventral tegmental area, decreased CO activity in the inferior rostral linear nucleus may be 
important to depression, but the exact role of the rostral linear nucleus of the raphe in 
depression-related behaviors remains to be elucidated.   
As mentioned in Chapter 1, hippocampal neurogenesis is thought to be 
compromised in depression [reviewed in (63, 64)].  Hippocampal neurogenesis is 
decreased by 13-cis-RA administration in male CD1 mice (97).  Although we don’t fully 
understand the role of the hippocampus or neurogenesis in depression-related behaviors, 
hippocampal volume is decreased in depressed patients as assessed with MRI (63-66).  
However, hypermetabolism has been observed in the hippocampus in the congenitally-
learned helpless rat (214) and human patients with major depressive disorder (215).  
Additionally, hippocampal metabolism is reduced following antidepressant treatment in 
humans (216).  This may indicate that there is some metabolic mechanism that 
compensates for neurogenesis loss.   
Interestingly, 5-HT appears to have a role in hippocampal neurogenesis and the 
removal of 5-HT reduces hippocampal neurogenesis (148).  Furthermore, in rats, 
serotonergic denervation reduces hippocampal neurogenesis (217), a phenomena that can 
be reversed by transplantation of fetal raphe nuclei cells into the hippocampus (218).  We 
were interested to find that dorsal raphe nuclei metabolism correlated to the hippocampal 
regions in the control mice but not the in the 13-cis-RA treated mice.  Perhaps this 
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uncoupling of the serotonergic system from the hippocampal system is, at least in part, 
responsible for the effects of 13-cis-RA on neurogenesis observed by others (97). 
Increases in somatodendritic autoinhibitory 5-HT1A levels may reduce 
serotonergic cell firing and thereby decrease 5-HT signaling.  Increases in SERT protein 
levels would lead to increased removal of 5-HT from the synaptic cleft, and therefore 
also decrease serotonergic signaling.  Since 13-cis-RA increased both the 5-HT1A and 
SERT proteins in vitro (197), it seems likely that should these two proteins be increased 
in vivo, they would lead to a decrease in serotonergic signaling that may ultimately 
decrease hippocampal neurogenesis.  However, more experiments would need to be done 
to determine if, in the 13-cis-RA treated animals, compromised hippocampal 
neurogenesis due to 13-cis-RA treatment leads to, or results from, uncoupling of the 
hippocampal regions from the dorsal raphe nuclei.  Interestingly, rats that underwent 
partial serotonergic denervation had increased CO levels in the CA3 region of the 
hippocampus (219).  However, when partial serotonergic denervation was combined with 
chronic variable stress, CO activity in the CA3 region was not different from control rats 
(219).  Thus, although 13-cis-RA may be leading to decreased serotonergic function,  
which could lead to increased metabolism in the CA3 region, the stress of the behavioral 
testing may have masked hippocampal hypermetabolism expected for a model of 
depression.   
As mentioned in Chapter 1, the habenula is a major regulator of monoaminergic 
transmission and receives inputs from the serotonergic and the norepinephrinergic 
systems as well as sending output to the serotonergic dorsal raphe nuclei (70, 71) and to 
the dopaminergic ventral tegmental area (71).   The ability of the lateral habenula to 
regulate monoaminergic function, which is often disrupted in depression, makes the 
lateral habenula a likely candidate for involvement in depression.  Additionally, 
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metabolic activity in the lateral habenula has been shown to be increased using 14C-2-
deoxyglucose uptake in three animal models of depression:  chronic-stress, amphetamine 
withdrawal, and alpha-methyl-para-tyrosine administration (200).  Moreover, the 
congenitally learned-helpless model of depression was found to have increased 
metabolism in the lateral habenula as assessed by CO activity (74).  
The lateral habenula has been found to negatively regulate the dorsal raphe nuclei 
(72, 212) and this inhibitory regulation of the dorsal raphe nuclei ultimately results in an 
excitatory regulation of the hippocampus by the lateral habenula (212).  A recent study 
by Yang et al. (73) used two models of depression in rats, chronic mild stress and 
neonatal exposure to clomipramine, to observe the effect of lateral habenula lesions on 
immobility in the forced swim test.  Lesions to the lateral habenula decreased immobility 
in the forced swim test in both models of depression and also led to an increase in 5-HT 
in the dorsal raphe nuclei (73).  Given that, in control animals, the lateral habenula is 
coupled to the dorsal raphe nuclei, which is coupled to the hippocampal CA1 region, the 
lateral habenula may be regulating the CA1 region of the hippocampus consistent with 
the pathway outlined by Ferraro et al. (212).  Additionally, the dorsal raphe nuclei sends 
projections to the CA3 region as well (208) and so this connection was included in the 
path analysis.  We also wanted to determine more specifically what the effects of 13-cis-
RA are on the hippocampus and we therefore included the hippocampal intrinsic pathway 
in the path analysis.  The path analysis performed here indicates that this excitatory 
control of the lateral habenula on the hippocampus via inhibition of the dorsal raphe 
nuclei may be disrupted by 13-cis-RA treatment.  However, the lateral habenula remains 
coupled to the CA1, perhaps representative of other pathways involved in lateral 
habenula/hippocampal regulation.  It is interesting to see that the intrinsic dentate gyrus 
→ CA3 → CA1 pathway within the hippocampus is increased after 13-cis-RA treatment 
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and may explain why the hippocampus seems to be functioning independently of the 
dorsal raphe nuclei.   
Decreased hippocampal neurogenesis may be responsible for the uncoupling of 
the hippocampus and the dorsal raphe nuclei and the disruption of the lateral habenula → 
dorsal raphe nuclei → hippocampal paths.  Decreased hippocampal neurogenesis may 
also account for the increased influences of the dentate gyrus on the CA3 region and the 
CA3 region on the CA1 region in 13-cis-RA treated animals.  However, it is difficult to 
determine if decreased hippocampal neurogenesis or decreased serotonergic signaling is 
caused by 13-cis-RA first, thereby leading to lateral habenula → dorsal raphe nuclei → 
hippocampal dysregulation, or if effects are happening simultaneously.  It is possible that 
13-cis-RA could target the lateral habenula first.  However, since 13-cis-RA increases 5-
HT1A and SERT protein levels in an isolated serotonergic cell system in vitro (197), 13-
cis-RA may have the ability to disrupt serotonergic signaling directly without having to 
disrupt serotonergic control by the lateral habenula first, ultimately resulting in the 
uncoupling of the dorsal raphe nuclei from the lateral habenula.   
It seems as though a loss of the lateral habenula → dorsal raphe nuclei → 
hippocampus pathway should lead to increased activity in the hippocampus since the 
inhibitory effect of the dorsal raphe nuclei is not present.  We expect that this would 
especially be true given that hippocampal activity is thought to be increased in depression 
(214) as mentioned above.  Ultimately, one might also expect the lateral habenula and the 
hippocampal regions to become functionally uncoupled, an outcome not observed in the 
interregional correlations calculated here.  Perhaps the loss of serotonergic function 
leading to decreased neurogenesis was not great enough to lead to the expected increased 
hippocampal activity in these mice, although the effects of 13-cis-RA are enough to lead 
to depression-related behaviors in these animals.   
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Lack of altered metabolism in the hippocampal regions may maintain the 
functional connectivity between the lateral habenula and the hippocampus.  However, 
loss of serotonergic to hippocampal functional connectivity may still result in depression-
related behaviors.  This especially seems to be the case because we saw an inverse 
correlation between the CO activity in the dentate gyrus and Total Immobility in the tail 
suspension and forced swim tests, indicating that the lower the dentate gyrus CO activity, 
the more immobility the animal exhibited.  Furthermore, this was only true in 13-cis-RA 
treated animals, where decreased neurogenesis is expected.  However, it is unknown if 
CO activity in the dentate gyrus is reflective of the level of neurogenesis occurring in the 
dentate gyrus.  We did not find a difference in hippocampal volume due to 13-cis-RA 
treatment here even though others have shown that 13-cis-RA treatment decreases the 
number of new neurons throughout the hippocampus (97).  Although 13-cis-RA may still 
be affecting neurogenesis in the animals in this study, volume measurements are probably 
not sensitive enough to reflect the effect of 13-cis-RA on neurogenesis.  
Evaluation of CO activity in the various brain regions of control and 13-cis-RA 
treated mice showed very few alterations in metabolic activity.  However, the 
serotonergic system and coupling of the serotonergic system to the hippocampus were 
affected by 13-cis-RA administration.  Specifically, not only did 13-cis-RA tend to 
decrease CO activity in the median raphe nuclei, but 13-cis-RA treatment uncoupled the 
functional connectivity of the dorsal raphe nuclei to the hippocampus.  This uncoupling 
of the dorsal raphe nuclei and the hippocampus may be a result of, or lead to, decreased 
hippocampal neurogenesis previously observed due to 13-cis-RA treatment.  
Additionally, animals with lower dentate gyrus CO activity exhibited higher levels of 
total immobility in the tail suspension and forced swim tests in the 13-cis-RA treated 
group.  Previously, we showed that 13-cis-RA increased 5-HT1A receptor and SERT 
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protein levels in vitro (197).  Ultimately, increased 5-HT1A and SERT protein levels in 
vivo may be decreasing serotonergic signaling, leading to decreased hippocampal 
neurogenesis, uncoupling of the lateral habenula from the dorsal raphe nuclei, and most 
importantly, increased depression-related behaviors. 
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Table 4.1:  Mean ± S.E.M. CO activity (µmol/min/g wet tissue weight) for control versus 
13-cis-RA treated animals. 













  Cortex 
2.68 224.0 ± 10.5 12 231.2 ± 12.9 12 0.67 
Cingulate  
  Cortex 2 
1.42 195.2 ± 14.7 11 211.9 ± 11.6 12 0.38 
Infralimbic 
  Cortex 
1.42 202.3 ± 10.8 11 213.6 ± 9.5 12 0.44 
Lateral Septal  
  Nucleus 
1.42 215.5 ± 8.0 11 221.2 ± 9.0 12 0.64 
Hippocampus       
   CA1 -1.94 240.8 ± 10.1 10 235.4 ± 10.6 11 0.72 
   CA3 -1.94 267.0 ± 8.7 10 280.0 ± 10.2 11 0.35 
   Dentate Gyrus -1.94 311.4 ± 10.2 10 310.2 ± 11.6 11 0.94 
Habenula       
   Median  -1.94 268.9 ± 10.6 10 260.2 ± 8.9 11 0.54 
   Lateral -1.94 348.9 ± 9.9 10 347.6 ± 9.0 11 0.92 
Paraventricular  
  hypothalamus 
-1.94 259.7 ± 10.0 12 266.0 ± 8.2 12 0.63 
Ventral  
  Tegmental Area 
-3.52 204.7 ± 7.8 12 195.2 ± 9.3 12 0.44 
Rostral Linear 
  Nucleus of the  
  Raphe 
      
     Superior -3.52 147.6 ± 10.1 12 143.8 ± 8.5 12 0.78 
     Inferior -3.52 152.7 ± 9.6 12 124.9 ± 8.1 12  0.03* 
Raphe Nuclei       
     Dorsal -4.36 313.8 ± 10.2 12 306.5 ± 13.5 11 0.67 
     Median -4.36 294.1 ± 9.8 12 267.7 ± 11.3  11  0.09† 
Subiculum -3.52 248.9 ± 8.4 12 254.1 ± 6.9 12 0.64 
Interpeduncular 
  Nucleus 
-3.52 351.0 ± 16.6 11 355.7 ± 20.0 12 0.86 
Somatosensory 
  1, barrel field  
-1.94 278.9 ± 8.5 11 297.4 ± 9.5 11 0.18 
       
Whole brain  
  averages 
     202.2 ± 1.9 12 202.0 ± 2.9 12 0.96 
*P < 0.05.   
†0.05<P < 0.10. 
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Table 4.2:  Summary of behavior to CO correlations and interregional correlations in 























TST immobility –  
  Dentate gyrus 
 








  < 0.001** 
Dorsal raphe nuclei –  
  CA1 
  CA3 
  Dentate gyrus 
 
 0.83 (p = 0.003) 
 0.82 (p = 0.004) 






-0.14 (p = 0.71) 
-0.07 (p = 0.84) 






  0.01* 
  0.02* 
0.11 
Lateral Habenula – 
  CA1 
  Dorsal raphe 
     nuclei§ 
 
 0.78 (p = 0.007) 





 0.91 (p < 0.001) 






  0.04* 
 
*Correlation for 13-cis-RA treated group is significantly different from correlation for 
control treated group as determined by the Fischer’s z test (p < 0.05).   
** Correlation for 13-cis-RA treated group is significantly different from correlation for 
control treated group as determined by Fisher’s z test (p < 0.001) 
§Correlations between dorsal raphe nuclei and lateral habenula were not significant in the 
control group after performing the modified jackknife (r = 0.51, p = 0.34) and 
correlations were not significantly different between groups for the dorsal raphe and 




Figure 4.1:  Bregma levels for CO readings. 
Slices are representative of the CO readings taken for each brain region. (A) Bregma 
level 2.68.  OFC = orbitofrontal cortex.  (B) Bregma level 1.42.  Cg2 = cingulate cortex 
2, IL = infralimbic cortex, LSN = lateral septal nucleus.  (C) Bregma level -1.94.  CA1 = 
Cornu Ammonis field 1 of the hippocampus, CA3 = Cornu Ammonis field 3 of the 
hippocampus, DG = dentate gyrus of the hippocampus, MH = median habenula, LH = 
lateral habenula, PVH = paraventricular hypothalamus.  (D) Bregma level -3.52.  SRLi = 
superior rostral linear nuclei of the raphe, IRLi = inferior rostral linear nuclei of the 
raphe, VTA = ventral tegmental area, IPN = interpeduncular nucleus.  (E) Bregma level -
4.36.  DRN = dorsal raphe nuclei, MRN = median raphe nuclei. 
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Figure 4.2:  Proposed path of control of hippocampus by lateral habenula via the dorsal 
raphe nuclei. 
Anatomical connections are represented by arrows.  The lateral habenula is known to 
have an effect on the CA1 region by acting on the dorsal raphe nuclei, but the dorsal 
raphe nuclei also send input to the CA3 region. 
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Figure 4.3: 13-Cis-RA treatment uncouples the dorsal raphe nuclei from the hippocampal 
regions. 
Interregional correlations between CO activity in the dorsal raphe nuclei and each of the 
hippocampal regions were determined as Pearson product moment correlations for 
control treated animals (A, B, C left column) or 13-cis-RA treated animals (A, B, C right 
column).  (A) The CO activity in the dorsal raphe nuclei significantly correlates to the 
CO activity of the CA1 region in control animals but not in 13-cis-RA treated animals.  
(B) The CO activity of the dorsal raphe nuclei significantly correlates to the CO activity 
of the CA3 region in control animals but not in 13-cis-RA treated animals.  (C) The CO 
activity of the dorsal raphe nuclei significantly correlates to the CO activity of the dentate 
gyrus in control but not 13-cis-RA treated animals.  (D) Comparisons of the correlations 
between control and 13-cis-RA treated animals.  *Correlation in 13-cis-RA treated 
animals is significantly different from correlation in control animals (p < 0.05). 
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Figure 4.4:  Communication between the hippocampus, the lateral habenula, and the 
dorsal raphe nuclei is lost due to 13-cis-RA treatment. 
The pathway by which the lateral habenula controls the CA1 region of the hippocampus 
via the dorsal raphe nuclei and the communication between the dorsal raphe nuclei and 
the hippocampus in (A) control animals and (B) 13-Cis-RA treated animals. Positive path 
coefficients are shown as solid lines.  Negative path coefficients are shown as dashed 
lines.  Path coefficients are indicated next to each arrow.  Magnitude of effect is 
represented by the thickness of lines.  The lines coming into each region without an 
annotated region themselves are the residual influence into the lateral habenula, 
hippocampus, or the dorsal raphe nuclei.  The regions exerting the residual influences are 
unknown.  n = 10 for both groups.  χ2diff(8) = 17.03, p = 0.03. 
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Figure 4.5:  Total time spent immobile in the tail suspension and forced swim tests 
correlates to the CO activity of the dentate gyrus in 13-cis-RA treated 
animals. 
The Total Immobility is the sum of the immobility during the last four min of the tail 
suspension and the forced swim tests.  Correlations between the Total Immobility and the 
CO activity of the dentate gyrus are Pearson product moment correlations for (A) control 
group and (B) 13-cis-RA treated group.  
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Figure 4.6: 13-Cis-RA has no effect on percent hemi-hippocampal area of hemi-section 
area. 
The percent hemi-hippocampal area was calculated at each bregma level for control and 
13-cis-RA treated mice.  There was no effect of treatment on % area as determined by a 
repeated measures ANOVA with an alpha level of 0.05.  For control animals, n = 7.  For 
13-cis-RA treated animals, n = 11.
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Figure 4.7:  Summary of the effects of 13-cis-RA on brain metabolism and functional 
connectivity. 
The lines represent correlations between brain regions and thickness of the line is 
representative of the correlation.  Solid lines represent positive correlations while dashed 
lines are negative correlations.  (A) Control group:  The hippocampal CA1 and CA3 
regions are coupled to the dorsal raphe nuclei.  Additionally, the dentate gyrus is also 
coupled to the dorsal raphe nuclei.  There was no correlation between immobility in the 
tail suspension and forced swim tests to any brain region in the control animals.  (B) 13-
Cis-RA treatment tends to decrease the CO activity in the median raphe nuclei and 
significantly decreased CO activity in the inferior rostral linear nucleus of the raphe.  13-
Cis-RA treatment also uncouples the dorsal raphe nuclei from the CA1 and CA3 regions 
of the hippocampus and uncouples the dorsal raphe nuclei from the dentate gyrus, where 
neurogenesis occurs.  Lastly, total immobility in the tail suspension and forced swim tests 
is negatively correlated to the dentate gyrus in 13-cis-RA treated animals only.  
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Chapter 5:  13-Cis-RA Has No Effect on Estimated Volume or Number 
of Serotonergic Neurons in the Median or Dorsal Raphe Nuclei 
ABSTRACT 
13-Cis-RA, a synthetic retinoid, is capable of inducing depression-related 
behaviors in adolescent male mice and tends to reduce median raphe nuclei CO activity.  
Because CO activity is tightly coupled to energy requirements for neuronal activity, 
reductions in CO activity represent decreased neuronal firing.  13-Cis-RA administration 
to male mice also uncouples the dorsal raphe nuclei from the hippocampus in vivo.  In 
serotonergic cells in vitro, 13-cis-RA treatment leads to increased protein levels of 5-
HT1A and SERT, two components of the serotonergic system that regulate serotonergic 
signaling.  Increases in these proteins in vivo could lead to decreased serotonergic 
signaling.  Interestingly, 5-HT is involved in hippocampal neurogenesis and removal of 
5-HT reduces hippocampal neurogenesis.  Others have found that 13-cis-RA decreases 
hippocampal neurogenesis.  Because 13-cis-RA is capable of inducing apoptosis, as are 
many retinoids, we hypothesized that reduction in the number of serotonergic cells in the 
dorsal and median raphe nuclei could account for the decrease in CO activity in the 
median raphe nuclei and the decreased hippocampal neurogenesis.  Adolescent male mice 
were treated with 1 mg/kg/day of 13-cis-RA for six weeks prior to examination of the 
median and dorsal raphe nuclei via stereological analysis of 5-HT immunopositive 
neurons.  There were no differences in the volumes or serotonergic cell densities in either 
the median or dorsal raphe nuclei, indicating that while 13-cis-RA is capable of 
disrupting the serotonergic system and its functional connectivity to the hippocampus, 
these disruptions are not due to decreased serotonergic cell numbers in the dorsal or 
median raphe nuclei. 
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INTRODUCTION 
Previously we showed that chronic 13-cis-RA administration induces depression-
related behaviors (173), tends to decrease CO activity the median raphe nuclei, and 
uncouples the dorsal raphe nuclei from the hippocampal region in adolescent male mice.  
Additionally, 13-cis-RA increases intracellular levels of 5-HT and the 5-HIAA and 
increases protein levels of the 5-HT1A receptor and SERT in serotonergic cells in vitro 
(197).  Furthermore, 13-cis-RA treatment decreases hippocampal neurogenesis in vivo 
(97). 
13-Cis-RA, a synthetic retinoid, is a member of the vitamin A family.  
Hypervitaminosis A is also thought to have effects on the mature nervous system and can 
cause headaches and psychosis.  Prior to our work, there have been relatively few studies 
examining the effects of retinoids in the mature central nervous system.  Instead, the 
retinoid field has historically focused on the role of retinoids in development and cancer 
chemotherapy where retinoids regulate cell differentiation and apoptosis (220). 
Postmortem stereological studies of depressed patients show decreased 
orbitofrontal cortex volume and decreases in glial cell number and size in the 
orbitofrontal cortex (221, 222), a region that has been shown to have decreased 
metabolism after four months of 13-cis-RA treatment (94).  Additionally, hippocampal 
volume is decreased in depressed humans (63-66).  It is not known if these volume 
reductions and decreases in glial cell numbers are due to atrophy or cell loss (222).  
However, antidepressant treatments are capable of upregulating cellular protective 
factors, such as Bcl-2, which blocks apoptosis (77).  Although very few studies have 
looked at volume changes in the dorsal and median raphe nuclei, one study found that 
while the volume of dorsal raphe nuclei was not different between suicide victims and 
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controls, the density of serotonergic cells in the dorsal raphe nuclei of suicide patients 
was higher than that of controls (223).   
5-HT is involved in regulation of neurogenesis and loss of 5-HT leads to 
decreased neurogenesis (148).  Denervation of median and dorsal raphe neurons by 5, 7-
dihydroxytryptamine decreased cell proliferation in the dentate gyrus as measured by 5-
bromo-2’-deoxyuridine immunostaining (217) and grafts of fetal serotonergic cells 
restored neurogenesis in denervated rats (218).  Thus, although the decreased 
hippocampal neurogenesis due to 13-cis-RA treatment may, in part, be due to direct 
effects of 13-cis-RA on differentiation in the dentate gyrus, decreased serotonergic 
signaling may also play a part in reducing neurogenesis. 
Given the effects that 13-cis-RA has on the serotonergic system (197), 
hippocampal neurogenesis (97), and the interactions between serotonergic and 
hippocampal functional connectivity (chapter 4), we asked what is the mechanism by 
which 13-cis-RA is disrupting these two systems.  To our knowledge, this is the only 
study that has taken a stereological approach to compare the effects of 13-cis-RA on 
number of 5-HT-labeled cells within the median and dorsal raphe nuclei and the volumes 
of these two regions.  Specifically, we determined if 13-cis-RA affected median and 




Young, adult male DBA/2J (Jackson Laboratories, Bar Harbor, ME) mice were 
used in this study.  Animals were three weeks old at arrival and four weeks old at the start 
of treatment.  Mice were group housed four per cage and maintained under a 12:12 h 
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light/dark cycle.  Food and water were provided ad libitum.  All procedures and tests 
performed on animals were approved by the University of Texas IACUC, protocol 
number 04100403, and according to the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. 
 
Treatment 
Animals were treated in the same way as described in Chapter 2 of this 
dissertation.  Briefly, animals were allowed to adapt to the University of Texas animal 
facility for one week prior to initial injection.  Animals were handled during the first 
week to reduce the stress of receiving daily injections.  A 2 mg/mL stock solution of 13-
cis-RA in DMSO was stored for up to one week at -20 ºC.  Sterile injection samples were 
prepared in the dark.  Injections were performed one hour prior to the start of the dark 
cycle in the same room where the animals were housed and one person performed all 
injections.  Treated animals (n = 11) received daily i.p. injections of 1 mg/kg/day 13-cis-
RA (Sigma, St. Louis, MO) dissolved in sterile 50% DMSO/50% saline (0.9%) to a final 
volume of 200 µL.  Control animals (n = 11) were administered 200 µL of vehicle (50% 
DMSO/50% saline), i.p., daily.  Animals were injected for 6 weeks.  No behavioral 
testing was performed on these animals. 
 
Perfusions 
Perfusions were performed as described in (224).  Briefly, mice were deeply 
anesthetized with 0.05 mL each ketamine (100 mg/mL)/xylazine (20 mg/mL) and then 
perfused transcardially with 1% paraformaldehyde for 30 s at a rate of 7.5 mL/min, 
followed by 4% paraformaldehyde for 10 min.  The brains were immediately removed 
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intact and postfixed in paraformaldehyde overnight followed by storage in phosphate 
buffer saline (PBS) with 0.1% sodium azide at 4°C.  Forty µm sections were then cut 
using a vibratome (Leica, Bannockburn, IL) and stored in PBS with 0.1% sodium azide at 
4°C until immunohistochemistry was performed. 
 
Immunohistochemistry for Stereological Analysis 
Sections were from a 1:3 series across the region containing both the dorsal and 
median raphe nuclei.  All washes were done in PBS, three times for 10 min each.  
Sections were washed at room temperature and then blocked for endogenous peroxides 
containing 3:1 methanol: 3% hydrogen peroxide for 15 min. The sections were then 
washed and blocked in SuperBlock (Pierce, Rockford, IL) containing 10% natural goat 
serum (NGS), 2% bovine serum albumin (BSA), and 0.2% Triton X.  The tissues were 
incubated in blocking solution (BS) consisting of PBS containing 10% Superblock, 10% 
NGS, 2%BSA, and 0.2% Triton X with a 1:10,000 dilution of anti-5-HT antibody (Cat # 
S5545, Sigma, Saint Louis, MO) for 24 h.  The sections were then washed and incubated 
for 1 h in biotinylated goat anti-rabbit IgG antibody at a 1:600 dilution in BS.  The 
sections were washed and incubated for 1 h in PBS containing 0.1% Triton X and avidin-
biotin-peroxidase (Vectastain ABC kit, Vector Labs, Burlingame, CA) according to 
manufacturer instructions.  Sections were washed and developed with diaminobenzidine 
(DAB) (Vector Labs, Burlingame, CA) for 6 min, rinsed twice in PBS for five min each 
and then washed overnight in PBS.  The tissues were then mounted on Superfrost Plus 
slides (Fisher Scientific, Pittsburg, PA) and allowed to dry for two days before 
counterstaining and dehydration.   
To Nissl counterstain, the slides were dipped in water 15 times, incubated in 
toliduline blue for 15 s, followed by 3 water washes for 30 s, each.  The sections were 
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then dehydrated (75% ethanol, 95% ethanol containing acetic acid, 95% ethanol, 100% 
ethanol, 100% ethanol), cleared in xylenes and coverslipped with permount. 
 
Stereological Analysis 
For stereological analysis, the Nissl-counterstained median and dorsal raphe 
nuclei regions were outlined at a low magnification (4X) on a live image with the help of 
a mouse atlas (205).  To demark the median raphe nuclei, the anterior or ventral 
tegmental nucleus was used to determine the most dorsal region of the median raphe 
nuclei, while the paramedian raphe nuclei and the tectospinal tract were used to 
determine the edges along the dorsal-ventral axis.  The most ventral region of the median 
raphe nuclei was identified by locating the pericentral reticulotegmental nucleus of the 
pons.   The slices of the median raphe nuclei used for the stereological analysis started at 
approximately -4.04 mm from Bregma and continued posterior to -4.96 mm from Bregma 
(Fig. 5.1A-K).   
The landmark used to help identify the most ventral region of the dorsal raphe 
nuclei was the superior cerebellar peduncle and the caudal linear nucleus of the raphe.  
The dorsal raphe nuclei extends into the periaqueductal gray area and the aqueduct was 
used as a landmark to determine the dorsal boundary of the dorsal raphe nuclei.  Because 
the 5-HT-labeled cells labeled similarly to the drawn regions of the dorsal raphe nuclei in 
the mouse brain atlas, 5-HT-labeled cells were also used to help determine the boundaries 
along the dorsal-ventral axis of the dorsal raphe nuclei.  The slices used for stereological 
analysis of the dorsal raphe nuclei started approximately -4.04 mm from Bregma and 
continued until approximately -5.02 mm from Bregma. (Fig. 5.1A-K).  
5-HT-labeled cells appeared brown and were easily identified (Fig. 5.1L-M).  A 
100X immersion oil, 1.35 numerical aperture objective was used to count cells during 
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stereological analysis.  The stereological analysis was performed similarly to that 
described in (225) using a computer-assisted morphometry system consisting of an 
Olympus BX61 photomicroscope (Center Valley, PA) equipped with a Mac5000 Manual 
joystick control (Ludel Electronic Products, Hawthorne, NY), a MicroFire S99808 video 
camera (Optronics, Goleta, CA), a Dell microcomputer (Dimension 4550 Series, Austin, 
TX), Cintiq 15X screen (Wacom, Vancouver, WA), and StereoInvestigator morphometry 
and stereology software (MicroBrightField, Inc., Colchester, VT) for both the control and 
13-cis-RA treated groups.  The StereoInvestigator software placed dissector frames using 
a systematic random design within each contour outlining each region on a 90 x 90-µm2 
grid for the median raphe nuclei and a 90 x 130-µm2 grid for the dorsal raphe nuclei.  5-
HT-labeled cells were counted within 45 x 45 µm optical dissector frames on the x-/y- 
axis and the final post-processing thickness of each section was measured by the 
microcator in the StereoInvestigator program.  The average height of the tissue was 15.65 
µm and 5-HT-labeled cells were counted over the whole thickness.  Although guard 
zones are often used in stereological analyses to prevent double-counting cells, most of 
the 5-HT labeling occurred in the tissue region closest to the edges and all tissues were 
counted the same way in both control and 13-cis-RA treated subjects, therefore the lack 
of guard zone should not affect the analysis.   
The 5-HT-labeled cells in the median and dorsal raphe nuclei were counted as two 
separate categories.  The neuronal number estimates were made using the optical 
fractionator and did not depend on a direct measurement of the volume of reference of 
the region considered.  Therefore tissue shrinkage during histological processing should 
not influence the neuronal number estimates. Stereological microscope analyses were 
performed at high power (100X) in a live computer image.   
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The volumes of the median and dorsal raphe nuclei were measured by drawing 
the contour plot of each region at 10X and then multiplying the contour area by the total 
thickness of the interslice distance.  Volume estimates were calculated based on 
postsprocessing tissues that have shrunk in all three directions.  No attempts were made 
to correct for shrinkage because shrinkage most likely differs in the z and x-y directions.  
Approximately nine slices were analyzed per subject for the median raphe nuclei and 10 
slices were analyzed per subject for the dorsal raphe nuclei.  The observer was blinded as 
to which treatment group the subject belonged during the stereological analysis. 
 
Statistical Analyses 
The average neuronal number estimate, volume, and neuronal density for the 
median or dorsal raphe nuclei were calculated on a group basis.  Two-tailed, Student’s t-
tests were performed to test for differences between vehicle control and 13-cis-RA 
treated animals in Excel (XP 2002; Microsoft).  Due to poor tissue quality in some of the 
subjects the final number of subjects for the regions varied.  For the median raphe nuclei, 
the analysis consisted of n = 8 and n = 10 for the control and 13-cis-RA treated groups, 
respectively.  For the dorsal raphe nuclei, the control group consisted of n = 7 subjects 
and the 13-cis-RA group contained n = 10.  Data are expressed as mean ± SEM. 
 
RESULTS 
13-Cis-RA Has No Effect on Number of 5-HT-labeled Neurons in the Median or 
Dorsal Raphe Nuclei 
There was no difference between the estimated number of 5-HT-labeled cells in 
either the median (p = 0.51) or dorsal (p = 0.53) raphe nuclei between the control and 13-
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cis-RA treated groups (Fig. 5.2).  Control animals exhibited an estimated 1815 ± 194 5-
HT-labeled cells in the median raphe nuclei while 13-cis-RA treated animals had and 
estimated 1954 ± 111 5-HT-labeled cells in the median raphe nuclei.  In the dorsal raphe 
nuclei, the estimated number of 5-HT-labeled cells was 7148 ± 377 in the control group 
and 7578 ± 424 in the 13-cis-RA treated group  (Fig. 5.2A).  There was no difference in 
volume of the median or dorsal raphe nuclei between control and 13-cis-RA treated 
groups.  The median raphe nuclei volume was 0.14 ± 0.02 mm3 in the control group and 
0.14 ± 0.01 mm3 in the 13-cis-RA treated group (p = 0.91).  In the control group, the 
volume of the dorsal raphe nuclei was 0.28 ± 0.02 mm3 while the volume of the dorsal 
raphe nuclei was 0.29 ± 0.01 mm3 in 13-cis-RA treated animals (p = 0.42) (Fig. 5.2 B).   
The total number of 5-HT-labeled cells/mm3 in the median raphe nuclei was not 
different between groups (p = 0.34) with the control group containing an estimated 12873 
± 743 cells/mm3 and the 13-cis-RA treated group containing 14119 ± 982 cells/mm3 (Fig. 
5.2C).  Lastly, the total number of 5-HT-labeled cells/mm3 in the dorsal raphe nuclei was 
not different between groups (p = 0.91) with the control group containing 26250 ± 748 
cells/mm3 and the 13-cis-RA treated group containing 26040 ± 1500 cells/mm3 (Fig. 
5.2C).  These data show that while 13-cis-RA is capable of disrupting serotonergic 
function, thereby leading to decreased serotonergic-hippocampal connectivity, this 
decreased connectivity is not due to decreased numbers of 5-HT-containing neurons in 
the median or dorsal raphe nuclei. 
 
DISCUSSION 
Chronic treatment with 13-cis-RA induces depression-related behaviors, 
decreases CO activity in the median raphe nuclei and uncouples the functional 
connectivity of the dorsal raphe nuclei and the hippocampus.  The tendency for CO 
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activity in the median raphe nuclei and loss of functional connectivity between the dorsal 
raphe nuclei to the hippocampus possibly leads to decreased hippocampal neurogenesis.  
However, the effects of 13-cis-RA on the mature brain and behavior are not due to 
serotonergic neuronal loss in the median or dorsal raphe nuclei.  There was no difference 
in estimated total serotonergic neuronal numbers between the control and 13-cis-RA 
treated groups for either the median or dorsal raphe nuclei.  Furthermore, there was no 
difference in estimated volume of median or dorsal raphe nuclei between control and 13-
cis-RA treated groups.  Lastly, serotonergic neuronal density was not different between 
groups in either the median or dorsal raphe nuclei. 
The etiology of depression remains unknown, but a current theory is that neuron 
loss due to apoptosis is an underlying cause of depression.  Because retinoids are such 
well-known mediators of cell cycle, differentiation, and apoptosis (220), the apoptotic 
theory seems very plausible in the case of 13-cis-RA induced depression.  Neuron loss 
due to apoptosis seems likely if orbitofrontal and hippocampal volumes are decreased 
(63, 64, 222) and glial cell numbers are reduced in depression (221, 222).  It should be 
noted that in the case of volume reduction of the hippocampus, many of these studies 
report that severity of volume reduction is proportional to the length of time the subject 
has had depression, and is not necessarily associated with age of the patient (226).  Thus, 
we do not know if the loss of neurons causes, or results, from depression.  Perhaps in an 
animal model of depression it is difficult to measure neuronal cell number or volume 
differences due to the shorter duration of animal studies.  This may especially be true if 
apoptosis is a result of depression.   
Apoptosis in the median raphe nuclei could account for the reduction of CO 
activity in the median raphe nuclei if neuronal loss also resulted in reduced dendritic 
input into this region.  Additionally, loss of serotonergic neurons in the dorsal raphe 
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nuclei could lead to the functional uncoupling of the dorsal raphe nuclei from the 
hippocampal regions.  Given that denervation of the serotonergic median and dorsal 
raphe nuclei leads to decreased hippocampal neurogenesis (217), it seems possible that 
serotonergic cell loss due to 13-cis-RA treatment could lead to the decrease in 
hippocampal neurogenesis also caused by 13-cis-RA treatment (97).  However, inhibition 
of 5-HT synthesis by parachloraphenylalanine leads to decreased hippocampal 
neurogenesis as well (148).  The reduction of hippocampal neurogenesis due to inhibition 
of 5-HT synthesis without denervation of the serotonergic neurons implies that it is the 
loss of 5-HT itself, and not the loss of the neuron that decreases neurogenesis (148).   
When considering the ways in which 5-HT might be reduced in the hippocampus, 
thereby leading to a decrease in neurogenesis, loss of 5-HT containing cell bodies due to 
13-cis-RA treatment is only one possible mechanism.  13-Cis-RA is capable of increasing 
protein levels of 5-HT1A receptor and SERT in vitro (197).  Since the 5-HT1A receptor is 
an autoinhibitory receptor, which prevents future firing of raphe neurons, and the SERT 
removes 5-HT from the synapse, increases in both of these proteins in vivo could lead to 
decreased 5-HT signaling in the hippocampus.  Increases in protein levels of the 5-HT1A 
receptor and SERT, if they were to occur in vivo, by 13-cis-RA treatment may account 
for the uncoupling of the functional connections between the dorsal raphe and the 
hippocampus observed with our CO activity assays (chapter 4).  Furthermore, increases 
in the 5-HT1A receptor and SERT may also lead to the decreased hippocampal 
neurogenesis observed by Crandall et al. (97).   Lastly, denervation does not necessarily 
mean loss of the cell body, but loss of the projections to the hippocampal region.  
Therefore, changes in morphology of serotonergic projections within the hippocampus by 
13-cis-RA might lead to reductions in neurogenesis.  
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Surprisingly, studies that have examined the effects of serotonergic denervation 
on depression-related behaviors have shown that denervation does not lead to increased 
depression-related behaviors in rats in the forced swim test (61, 62).  Serotonergic 
denervation in these studies lasted for approximately three weeks.  These negative results 
may imply that loss of 5-HT itself is not enough to induce depression.  Moreover, the 
lack of depression-related behavior due to serotonergic denervation might be 
representative of other phenomena occurring in depression, such as the loss of feedback 
loops between brain regions, that take longer to occur than the three weeks of induced 
serotonergic denervation.  Unfortunately, we don’t know the exact mechanism by which 
13-cis-RA is able to induce depression-related behaviors, but the mechanism does not 
appear to involve decreases in 5-HT-labeled neurons or volume changes in the median 
and dorsal raphe nuclei. 
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Figure 5.1:  Photomicrographs of 5-HT-labeled/Nissl stained tissue sections used for 
stereology for the dorsal raphe nuclei and the median raphe nuclei. 
A-K Serial sections from the mouse brain taken for stereology.  Sections were from a 1:3 
series and are immunoreactive for 5-HT.  They were Nissl stained to help identify the 
median and dorsal raphe nuclei.  The 4X photomicrographs have representative contour 
plots drawn on them to show the boundaries of the regions examined.  MRN = median 
raphe nuclei.  DRN = dorsal raphe nuclei.  L-M Higher power magnification (40X and 
100X respectively) of 5-HT-labeled dorsal raphe nuclei tissue to show a representative 
density and ability to identify 5-HT-labeled neurons. 
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Figure 5.2:  13-Cis-RA has no effect on the number of serotonergic neurons or the 
volume of the median or dorsal raphe nuclei. 
Stereology was performed on 40 µm slices taken from a 1:3 series over the median and 
dorsal raphe nuclei to determine (A) number of 5-HT-labeled neurons, (B) volume, and 
(C) serotonergic neuron density. 
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Chapter 6:  Summary, Future work, and Conclusions 
SUMMARY 
13-Cis-RA is a known teratogen and the role of 13-cis-RA, as well as many other 
retinoids, in development is widely studied.  However, there are significantly fewer 
studies concerning the effects of 13-cis-RA and other retinoids on the adult central 
nervous system.  Additionally, although the medical literature suggests that 13-cis-RA 
can cause depression, whether or not 13-cis-RA can cause depression has remained 
controversial.  Case studies have reported that onset of depressive symptoms can occur 
after initiation of 13-cis-RA treatment and these symptoms are relieved after cessation of 
the drug treatment (80).  Additionally, some cases have reported that depressive 
symptoms can reoccur with 13-cis-RA rechallenge (81).  Perhaps this should be enough 
evidence that 13-cis-RA can cause depression, but only approximately 8% of the 
population that takes 13-cis-RA become depressed (78).   
The research discussed within this dissertation has shown, most notably, that 13-
cis-RA can induce depression-related behaviors.  In our behavioral studies, immobility in 
the tail suspension and forced swim tests was used as a measure of depression-related 
behaviors (173).  Chronic 13-cis-RA administration to adolescent male mice increased 
immobility in both the tail suspension and forced swim tests.   Importantly, the increased 
immobility due to 13-cis-RA treatment was not due to decreased motor function or 
coordination.  13-Cis-RA treated animals exhibited the same amount of total mobility in 
the open field as controls.  In addition, 13-cis-RA treated animals tended to perform 
better in the rotarod test at low rotational speeds.  Although our method of measuring 
retinoids did not discriminate between ATRA and 13-cis-RA, serum levels of total 
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retinoids were found to be higher in 13-cis-RA treated animals, consistent with human 
patient data available.   
Of the neuronal networks currently thought to be involved in depression, the 
serotonergic system, which is commonly targeted by antidepressants, appears to be a 
target of 13-cis-RA.  In vitro, 13-cis-RA can increase intracellular levels of 5-HT and 5-
HIAA, the metabolite of 5-HT, and can increase protein levels of the 5-HT1A 
autoinhibitory receptor and SERT (197).  The 5-HT1A autoreceptor located on the raphe 
nuclei acts as an inhibitory receptor that, when activated by 5-HT, leads to inhibition of 
raphe nuclei firing.  SERT transports 5-HT from the synaptic cleft back into the raphe 
nuclei, therefore terminating 5-HT signaling once the neuron has fired.  Ultimately, 
increases in the 5-HT1A and SERT proteins, if they occurred in vivo, would reduce 
serotonergic neuronal firing.   
Chapter 4 shows that, in vivo, 13-cis-RA treatment tends to decrease CO activity, 
a measure of neuronal firing, in the median raphe nuclei.  We do not know if the 
tendency for 13-cis-RA to decrease median raphe nuclei activity is due to increases in 5-
HT1A receptor or SERT levels.  Increased 5-HT1A and SERT proteins in vivo might have 
greater impact at the terminal sites of serotonergic neurotransmission rather than on the 
cell bodies themselves.  Thus, should increases in 5-HT1A receptors and SERT occur in 
vivo, activity of 5-HT1A and SERT at the terminals of serotonergic dendrites may be 
responsible for the uncoupling of functional connectivity between the dorsal raphe nuclei 
and the hippocampal regions.   
Not only does the dorsal raphe nuclei become uncoupled from the hippocampus, 
but it also loses some connectivity to the lateral habenula, a major regulator of 
monoamine function.  Although there are no direct connections between the lateral 
habenula and the hippocampus, there are indirect connections between the lateral 
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habenula and the hippocampus through the dorsal raphe nuclei.  In fact, one pathway by 
which the lateral habenula may control the hippocampus is through inhibitory effects on 
the dorsal raphe nuclei.  13-Cis-RA treatment disrupts this pathway, perhaps forcing 
another pathway of habenula → hippocampal control to compensate.  
The uncoupling of functional connectivity between the dorsal raphe nuclei and the 
hippocampus due to 13-cis-RA treatment may also be reflective of decreased 
hippocampal neurogenesis due to 13-cis-RA, such as was observed in young adult mice 
by Crandall et al. (97).  Only in the 13-cis-RA treated animals, where neurogenesis is 
expected to be decreased, did a lower CO activity in the dentate gyrus strongly predict 
increased total immobility in the tail suspension and forced swim tests.  Thus, the more 
the dentate gyrus CO activity is decreased by 13-cis-RA, the greater the immobility the 
animal will exhibit. 
Because retinoids have the ability to induce apoptosis, we hypothesized that 
decreased CO activity in the median raphe nuclei could simply be due to neuron loss.  
Furthermore, because 5-HT has a role in maintaining neurogenesis, removal of 5-HT 
could contribute to the decreased neurogenesis by 13-cis-RA treatment and removal of 5-
HT from the hippocampus would also be accomplished by cell loss.  However, this was 
not the case as 13-cis-RA had no effect on total number of 5-HT-labeled neurons in either 
the median or dorsal raphe nuclei; nor did 13-cis-RA affect the volume of the median or 
dorsal raphe nuclei.  The stereological study performed here does not discount the fact 
that 13-cis-RA may have an effect on number of serotonergic inputs into the 
hippocampus.  Decreased dendritic input into the hippocampus could also decrease 
serotonergic signaling and therefore reduce neurogenesis.  Dendritic loss may also 
account for decreased functional connectivity between the dorsal raphe nucleus and the 
hippocampus.  However, in reality, the effects of 13-cis-RA on the serotonergic system 
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and the hippocampus are probably a combination of morphological changes and increases 
in 5-HT1A receptor and SERT levels as well as other mechanisms leading to decreased 
hippocampal neurogenesis.   
Although the work in this dissertation focused on the serotonergic system, other 
monoaminergic systems are known to be involved in depression and it is possible for 
these other monoaminergic systems to be targeted by 13-cis-RA, as mentioned in chapter 
1. Table 6.1 summarizes all the effects of retinoids on behavior and the monoaminergic 
systems.  However, other studies have pointed toward the disruption of the serotonergic 
system by retinoids as well.  Ferguson et al. (39) showed there was an apparent increase 
in 5-HT and 5-HIAA levels in the striatum of adult male rats administered 13-cis-RA.  
Additionally, mice fed a vitamin A deficient diet for 4 weeks tended to have lower levels 
of 5-HT in striatal tissue homogenate (40).  Given all this information, it appears as 
though 13-cis-RA may be targeting the serotonergic and hippocampal systems.  
Disruptions of the serotonergic system by 13-cis-RA may lead to, or even result from, 
decreased hippocampal neurogenesis.  Furthermore, decreases in serotonergic signaling 
and hippocampal neurogenesis, and the uncoupling of these two systems, by 13-cis-RA 
administration may cause depression-related behavior. Surprisingly, the increases in 5-
HT1A and SERT by 13-cis-RA in vitro were not due to increased transcription, and 
therefore, the effects of 13-cis-RA on the mature brain may not be occurring via the 
traditional RAR-mediated manner.  Figure 6.1 summarizes the effects of 13-cis-RA on 
the adolescent brain as observed here and by others, proposing a mechanism by which 





Of the many future directions that this study could take, the first study that comes 
to mind is to define the timeline for which 13-cis-RA administration induces depression-
related behaviors.  Additionally, because it is currently unknown if decreased 
hippocampal neurogenesis is a cause or a result of depression, insight could be gained by 
determining if depression-related behaviors are induced prior to, or after hippocampal 
neurogenesis is decreased.  Furthermore, the timing at which the dorsal raphe nuclei 
becomes uncoupled from the hippocampal structures should be examined.  Examining the 
uncoupling of these two regions, via CO activity and correlations, may advance 
understanding concerning the underlying structures and functions of each region of the 
hippocampus in relation to the serotonergic systems.  For instance, if decreased 
serotonergic signaling is leading to a reduction in neurogenesis in the dentate gyrus, the 
dentate gyrus may become functionally uncoupled from the dorsal raphe nuclei before the 
CA1 and CA3 regions do. 
Due to the fact that 13-cis-RA leads to an increase in 5-HT1A and SERT proteins 
in vitro, it is relevant to investigate the effect of 13-cis-RA on these two proteins in vivo.  
Fluorescent co-labeling of tissues with antibodies directed toward the 5-HT1A and SERT 
would be useful in identifying the autoinhibitory 5-HT1A receptors on the raphe nuclei 
themselves.  Since SERT is primarily located on serotonergic neurons, SERT would be 
used to identify presynaptic 5-HT1A receptors on co-labeled synapses.  It is expected that 
there would be increased 5-HT1A receptors and SERT in the median and dorsal raphe 
nuclei as well as on the raphe nuclei terminals in the raphe nuclei projection sites such as 
the prefrontal cortex and in the hippocampus.  
Additionally, electrophysiology recordings could be used to validate the 
disruption of the lateral habenula → dorsal raphe nuclei → hippocampus pathway by 13-
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cis-RA.  Electrophysiology could also verify that the median raphe nuclei has reduced 
firing activity due to 13-cis-RA treatment.  However, the electrophysiology techniques 
would be very difficult to perform in a mouse and validation of the findings in this 
dissertation would need to be performed in a rat in order to do these recordings.  
Validation in a rat model would also yield interesting information and insight.  Given that 
the adult rats in the studies conducted by Ferguson et al. (98) did not have induced 
depression-related behaviors, if adolescent rats administered 1 mg/kg/day of 13-cis-RA 
via i.p. injection displayed induced depression-related behaviors, it may be because the 
method of drug administration or the age is important to the induction of depression-
related behaviors.  To determine the influence of age on the ability of 13-cis-RA to cause 
depression-related behaviors, both adolescent and adult rats would need to be tested.  In 
fact, our collaborator, Dr. Sarah J Bailey at Bath University, Bath, UK, is conducting 
these studies.  Understanding the influence of 13-cis-RA on the components of the 
serotonergic system as well as the uncoupling of the serotonergic system from the 
hippocampus, and the age at which an animal is susceptible to these events would offer 
great insight into the etiology of depression. 
 
CONCLUSIONS 
Perhaps the predominant remaining question of this study is, if 13-cis-RA can 
induce depression, why do only 8% of the patients that are treated with Accutane have 
depressive symptoms, become depressed, or have thoughts of suicide?  This question is 
probably answered by susceptibility to depression in the general population or a genetic 
background predisposing a person to depression.  Tryptophan depletion studies have 
shown that depleting tryptophan in a normal human does not cause depression (60).  
However, depleting tryptophan in the diet of remitted depressed patients can lead to the 
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recurrence of depressive symptoms in these patients (59).  Furthermore, tryptophan 
depletion has mood lowering effects in people who have a family history of depression, 
even if the person has not been depressed himself (56) and in people with the short allele 
SERT polymorphism, even if they have not experienced depression (227).  It seems, then, 
that if 13-cis-RA is indeed affecting the serotonergic system, there may exist a human 
subpopulation, such as people with polymorphisms in the 5-HT1A receptor or SERT gene, 
that is susceptible to becoming depressed while taking Accutane.  
Although these experiments, to the general public, may seem like an investigation 
into the potential side-effects of a drug, examining the mechanisms by which 13-cis-RA 
induces depression-related behaviors may yield greater understanding into the underlying 
etiology and potential treatments of depression.  Since depression is a serious, debilitating 
disease, the use of pharmacological drugs that could induce depression should be 
carefully administered and patients taking them should be monitored closely.  This study 
also brings to light the need to perform behavioral assessments on drugs prior to clinical 
trials, especially if the drug is intended to treat non-life threatening conditions. 
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Table 6.1.  Effect of retinoid deficiency and excess on behavior, cellular, and 
monoaminergic systems 
System Retinoid Deficiency Retinoid Excess 
Behavioral ↓ Depression (28) 
↓ Anxiety (28) 
 
↓ Spatial learning (121, 147) 
↑ Depression (110, 173) 
↑ Anxiety (107, 110)  
↑ Irritability (107, 110)  
↓ Spatial learning (97) 
Cellular   
Energy 
Metabolism 
N/D ↓ Orbitofrontal cortical  
 glucose metabolism (94) 
 
↓Coupling of the dorsal raphe 
nuclei from the hippocampus 
Neurogenesis N/D ↓ Hippocampal 
neurogenesis (97) 
Monoamine Systems   
Norepinephrinergic ↑ Limbic NE (28) N/D 
Serotonergic ↓Striatal 5-HT and 5-HIAA 
(40) 
↑ Striatal 5-HT and 5-HIAA 
(39) 
 
↑ Intracellular 5-HT, 5-HT1A, 
and SERT (197) 
Dopaminergic ↓Striatal DA and DOPAC  
(40) 
↑ Tyrosine hydroxylase (37) 
↑ Monoamine oxidase B (38) 
↑ Striatal homovanillic acid 
(39) 
N/D = Not Determined 





Figure 6.1:  Summary of the effects of retinoids leading to depression-related behavior. 
Solid lines between brain regions represent positive correlations or path coefficients 
while dashed lines represent negative correlations or path coefficients.  (A) In control 
animals, the serotonergic system is coupled to the hippocampal regions and the lateral 
habenula is connected to the hippocampus via the dorsal raphe nuclei.  (B) Known 
changes due to retinoids measured either in vivo or in vitro are represented in blue.  
Yellow highlights indicate changes that were discovered through the work discussed in 
this dissertation.  Although the 5-HT1A receptor and SERT are present in untreated 
animals to maintain appropriate control of the raphe nuclei, 13-cis-RA might increase the 
5-HT1A receptor and SERT levels in vivo, as it does in vitro, causing increased 
suppression of the serotonergic system.  Furthermore, decreased raphe nuclei activity 
may be uncoupling the dorsal raphe nuclei from the hippocampal regions.  Ultimately, 
13-cis-RA may be decreasing serotonergic function and hippocampal neurogenesis.  
Decreased hippocampal neurogenesis may, in part, result from decreased serotonergic 
signaling.  Decreased serotonergic signaling and/or decreased neurogenesis due to 13-cis-
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